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ABSTRACT 
Type 1 diabetes (T1D) is a disease with no cure or prevention.  In T1D, the insulin-
producing pancreatic beta cells are impaired or lost due to a chronic autoimmune 
process, leading to a need for a life-long insulin treatment. Genetic predisposition 
determines the susceptibility to develop T1D but exogenous factors also contribute 
to pathogenesis. For example, numerous epidemiological studies have connected 
enterovirus infections to T1D. The aim of this study was to develop and evaluate 
methods for the detection of enteroviruses in cell and tissue samples. Furthermore, 
the aim was to employ these methods to assess the possible role of enteroviruses 
in the process leading to T1D by analyzing tissue samples from organ donors with 
T1D or T1D-related autoantibodies.  
A commercially available in situ hybridization (ISH) technology was applied for the 
detection of enterovirus genome in formalin-fixed paraffin-embedded (FFPE) tissue 
sections. Enterovirus-specific probes that recognize selected regions from the viral 
genome were designed using advanced bioinformatics tools and validated in 
samples from virus-infected cell cultures and mice. The results showed that the ISH 
method enabled detection of enteroviruses in both human cells and mouse tissues 
infected with enteroviruses. In addition, the probes could be designed and 
optimized to bind either a single enterovirus type or alternatively a wide range of 
different enterovirus types.  
Comparison of different enterovirus detection techniques in frozen and FFPE human 
cells containing different amounts of enterovirus-infected cells showed that RT-
qPCR was the most sensitive method in frozen samples giving a positive signal in the 
most diluted sample (10-8), followed by proteomics (10-7). Immunohistochemistry 
(IHC) with a commercial enterovirus VP1 antibody detected enterovirus in FFPE 
samples at dilution 10-6, and ISH at dilution 10-4.  
To assess enterovirus presence, the most sensitive methods were then employed to 
analyze a unique set of samples collected from cadaver organ donors in the Juvenile 
Diabetes Research Foundation (JDRF) funded Network for Pancreatic Organ Donors 
with diabetes nPOD. To assess enterovirus positivity, FFPE pancreas, spleen, 
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duodenum and pancreatic lymph node samples from T1D donors, donors positive 
for T1D -associated autoantibodies (AAb+) and non-diabetic control donors were 
immunostained using a commercial enterovirus VP1 antibody. As a result, 
enterovirus protein was found in tissues of T1D donors more frequently compared 
to control donors; in pancreas 70 % vs. 33 % (only insulin-positive organs included), 
in duodenum 40 % vs. 14 %, and in spleen 40 % vs. 26 %. Pancreatic lymph nodes 
were only available from a few T1D (N=9) and AAb+ (N=1) donors, and 56 % and 
100 % of these were enterovirus-positive, respectively. When RT-qPCR was applied 
to detect enterovirus genome in frozen tissue samples, viral RNA was detected in all 
organs, except in the duodenum, but less frequently than viral protein. When 
enterovirus positive pancreata were studied with markers of antiviral response 
(class I HLA, MxA and PKR), it was observed that in T1D donors, the enterovirus 
positive islets expressed strongly class I HLA molecules and MxA. However, such HLA 
hyperexpression or MxA upregulation was not seen in enterovirus positive islets in 
control donors. This finding suggests that virus-induced cytokine responses may 
differ between the groups.  
In conclusion, an enterovirus-specific in situ hybridization method was developed 
for fixed cell and tissue samples. This method was tailored by probe design to detect 
either a specific enterovirus type or a wide range of different enteroviruses. 
However, the method did not reach the sensitivity needed for human tissue samples 
with low viral titers. Analysis of a large set of tissue samples from T1D and non-
diabetic organ donors showed that enterovirus protein was more frequent in tissues 
of T1D donors compared to control donors. In addition, the proportion of 
enterovirus RNA-positive samples was much lower than that of samples positive for 
the viral VP1 protein. Certain anti-viral response markers were also more strongly 
expressed in the infected islets of T1D donors compared to control donors, 
particularly those markers that reflect intercellular communication via interferon 
signaling, which may contribute to the immune-mediated pathogenesis of T1D.  
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TIIVISTELMÄ 
Tyypin 1 diabetes on sairaus, johon ei ole parannuskeinoa eikä ennaltaehkäisevää 
hoitoa. Tyypin 1 diabeteksessa insuliinia tuottavat haiman beetasolut ovat 
vaurioituneet tai tuhoutuneet kroonisen autoimmuuniprosessin seurauksena, mikä 
johtaa elinikäisen insuliinihoidon tarpeeseen. Geneettinen alttius määrittelee 
taipumuksen sairastua, mutta tämän lisäksi tarvitaan ympäristötekijöiden vaikutus. 
Esimerkiksi lukuisat epidemiologiset tutkimukset ovat liittäneet enterovirusinfektiot 
tyypin 1 diabetekseen. Tämän tutkimuksen tavoitteena oli kehittää ja vertailla 
menetelmiä, joilla pystytään tunnistamaan enterovirus solu-  ja kudosnäytteistä. 
Lisäksi tavoitteena oli soveltaa näitä menetelmiä diabeetikoiden ja 
esidiabeetikoiden kudosnäytteiden analysointiin enterovirusten osuuden 
selvittämiseksi tyypin 1 diabeteksen tautiprosessissa.  
Kaupallista in situ hybridisaatio-teknologiaa käytettiin enteroviruksen genomin 
paikallistamiseen formaliinilla fiksatuista ja parafiiniin valetuista (FFPE) 
kudosleikkeistä. Enterovirukselle spesifisiä ja viruksen genomin tunnistavia 
koettimia suunniteltiin ja niiden toimivuus testattiin eri enteroviruksilla 
infektoiduilla soluviljelynäytteillä ja infektoitujen hiirten kudosnäytteillä. 
Menetelmä pystyi toteamaan viruksen näistä näytteistä ja tunnistuksen tarkkuutta 
voisiin säädellä koettimien sekvenssiä muuntelemalla siten, että menetelmä 
tunnisti joko laajakirjoisesti monia eri enteroviruksia tai vain yhtä enteroviruksen 
alatyyppiä.  
Eri enteroviruksen tunnistusmenetelmien keskinäinen vertailu viruksella 
infektoitujen humaanisolujen laimennossarjassa (jää- ja FFPE –näytteet) osoitti, että 
jäänäytteissä herkimmät menetelmät olivat RT-qPCR tunnistaen enteroviruksen 
laimeimmastakin näytteestä (10-8) ja proteomiikka (10-7). Immunohistokemia 
kaupallisella enterovirus VP1-vasta-aineella tunnisti enteroviruksen FFPE-näytteistä 
10-6 laimennoksesta ja ISH puolestaan 10-4 laimennoksesta. 
RT-qPCR:ää ja immunohistokemiaa käytettiin  Network for Pancreatic Organ Donors 
with Diabetes (nPOD) -projektin kudoskokoelman analysointiin seuraavista 
elinluovuttajaryhmistä: tyypin 1 diabeetikot (T1D), autovasta-ainepositiiviset 
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esidiabeetikot (AAb+) ja elinluovuttajat, joilla ei ollut diabetesta (verrokit). 
Parafiinileikkeitä haimasta, pernasta, ohutsuolesta ja haiman imusolmukkeista 
värjättiin kaupallisella enterovirus VP1-vasta-aineella. Värjäykset osoittivat, että 
enteroviruksen proteiinia löytyy diabeetikoiden kudoksista useammin kuin 
verrokkien; haimassa 70 % vs. 33 % (vain insuliinipositiiviset elinluovuttajat laskettu 
mukaan), ohutsuolessa 40 % vs. 14 % ja pernassa 40 % vs. 26 %. Haiman 
imusolmukenäytteitä analysoitiin vain 10 elinluovuttajalta (9 T1D ja 1 AAb+) ja 
näistä 56 % ja 100 % oli enterovirus-positiivisia. Lisäksi samoista kudoksista 
analysoitiin jäänäytteitä RT-qPCR:llä enteroviruksen genomin tunnistamiseksi. 
Enteroviruksen RNA:ta löydettiin kaikista muista kudoksista paitsi ohutsuolesta, 
mutta selvästi harvemmin kuin enteroviruksen proteiinia. Kun enterovirus-
positiivisia haimanäytteitä värjättiin vasta-aineilla, jotka tunnistavat 
virusinfektiovasteeseen liittyviä soluproteiineja isäntäsoluissa (HLA I, MxA ja PKR), 
huomattiin, että diabeetikoiden enterovirus-positiiviset saarekkeet ilmensivät 
voimakkaasti HLA I:stä ja MxA:ta. Verrokeiden enterovirus-positiivisissa 
saarekkeissa näiden markkereiden ilmentyminen oli normaalia. Tämän perusteella 
voidaan spekuloida, että virusinfektion aikaansaamat sytokiinivasteet poikkeavat eri 
ryhmien välillä.  
Yhteenvetona, työssä kehitettiin enteroviruksen RNA:ta solu- ja kudosnäytteistä 
tunnistava in situ hybridisaatiomenetelmä. Menetelmän kykyä tunnistaa eri 
enterovirustyyppejä pystyttiin säätelemään koettimien sekvenssiä muuntelemalla. 
Menetelmän herkkyys ei kuitenkaan ollut riittävä viruksen tunnistamiseksi 
humaanikudosnäytteestä, jossa viruksen määrä on alhainen. Diabeetikoiden ja 
verrokkien kudosnäytteitä analysoitaessa huomattiin, että enterovirukset ovat 
yleisempiä diabeetikoiden kudoksissa kuin verrokkien. Lisäksi, virus-RNA-
positiivisten näytteiden lukumäärä oli selvästi pienempi kuin virusproteiinille 
positiivisten määrä. Lisäksi erityisesti interferonivälitteiseen solujenväliseen 
vuorovaikutukseen liittyvät virusvastetta ilmaisevat merkkiaineet olivat 
infektoituneissa saarekkeissa diabeetikoilla selvästi enemmän koholla kuin 
verrokeilla, mikä saattaa osaltaan vaikuttaa taudin immuunivälitteiseen syntyyn. 
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1 INTRODUCTION 
T1D is an important and complex disease, affecting millions of people worldwide 
but primarily in Western countries. It mainly affects children or young adults. The 
financial burden is massive, as a life-long insulin treatment, surveillance, and follow-
ups are obligatory. The etiology of the disease is complex; it most likely has multiple 
triggers and, thus, varying pathways that ultimately lead to the same end point, the 
loss of insulin production. The insulin-producing beta cells of the pancreatic islets 
(Islets of Langerhans) are affected or destroyed during development of T1D. This 
leads to loss of insulin, which is needed to maintain the glucose homeostasis. 
Affected individuals face severe complications or even death if treatment is 
insufficient or comes too late. Since there is no cure or prevention for the disease, 
it is imperative to identify not only the cause(s) and trigger(s) of the disease, but 
also the underlying mechanism that ultimately results in the destruction of the 
insulin-producing cells. 
This study focuses on one of the most important potential triggers of T1D, 
enteroviruses, and development of techniques that can be used to detect these 
viruses with high sensitivity and specificity. More importantly, the presence of 
enteroviruses in the tissue samples between T1D patients, prediabetic individuals 
and non-diabetic controls was compared. In addition, selected markers of anti-viral 
immune response were assessed in enterovirus positive pancreas to identify 
possible differences in host’s antiviral response between T1D patients and control 
subjects. 
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2 REVIEW OF LITERATURE 
2.1 Enteroviruses 
2.1.1 Classification, structure and replication cycle 
The genus Enterovirus belongs to the family Picornaviridae, one of the largest virus 
families. Picornaviruses are grouped into 40 genera, and the genus Enterovirus 
comprises 15 species: Enterovirus A-L and Rhinovirus A-C. Seven of these 15 species, 
namely Enterovirus A-D and Rhinovirus A-C, are associated with human diseases (Fig. 
1). Different species comprise different enterovirus types. Enterovirus types are 
classified by sequencing a specific genomic region encoding the structural VP1 
protein. Species A-D alone comprise altogether 116 different virus types that infect 
humans. The number of different enterovirus types has been constantly increasing 
over the years due to the sequencing of new clinical isolates and identification of 
new enterovirus types from ongoing studies. (1,2) 
 
 
Figure 1.  Classification of the family Picornaviridae and the genus Enterovirus. In the genus 
Enterovirus the seven species that infect humans are depicted. Representative types for each of 
the seven enterovirus species are shown.  
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The enterovirus virion, like other picornaviruses, is spherical and approximately 30 
nm in diameter. The capsid surrounding the naked RNA genome has an icosahedral 
symmetry of 60 protomers. Each protomer comprises four capsid proteins called 
VP1, VP2, VP3 and VP4. VP1-VP3 are located on the surface of the capsid and VP4 
on the internal side of the capsid (3) (Fig. 2 A). The major capsid proteins VP1-VP3 
have a common topology, forming an eight-stranded beta barrel structure that is 
joint together by loops in variable lengths. The loop regions are also the sites where 
the main structural differences are found. Connecting loops project onto the surface 
of the virion where they make up the antigenic sites and give rise to the 
immunological diversity of virus types in Enterovirus genus (4,5).  
 
 
Figure 2.  A. Enterovirus structure. Enterovirus is a non-enveloped particle with icosahedral symmetry, 
constituted of 60 copies of four structural proteins VP1-VP4. These VPs assemble into protomers 
(marked in red), five protomers form a pentamer (marked in green) and 12 pentamers plus the viral 
genome that is packaged inside the capsid form a virion.  B. The RNA genome of enterovirus is 
approximately 7.5 kb in length with 5’ / 3’ UTRs and VPg / polyA in 5’ and 3’ ends, respectively. 
During viral replication, the RNA genome is translated into a polyprotein that is sequentially cleaved 
by viral proteases 2A, 3CD and 3C, to form mature structural and non-structural proteins. (Adapted 
from Yi et al 2017 (6)) 
A 
B 
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Enteroviruses have a positive-sense, single-stranded RNA (+ssRNA) genome, which 
is approximately 7.5 kb in length. The genome has a single open reading frame (ORF) 
flanked by 5´and 3´untranslated regions (UTRs) and a small protein (VPg) covalently 
attached to the 5’ terminus (Fig. 2B). The VPg is unique for picornaviruses and 
important in the RNA replication process (7). The coding region of enteroviruses is 
divided into three sub-regions, named P1, P2 and P3, where P1 encodes the 
structural proteins that form the outer capsid of the viral particle. Conversely, P2 
and P3 encode seven non-structural proteins that are responsible for the enzymatic 
processes, such as the proteolytic cleavage that releases the structural proteins and 
the RNA-dependent RNA polymerase (Fig. 2) (6).  
The primary replication of enteroviruses occurs in cells of mucosal tissue of 
gastrointestinal and respiratory tracts. Replication cycle begins when the virus 
recognizes and binds a host receptor, which mediates the endocytosis of the virus. 
Viral RNA is released into the cytoplasm after entrance and is directly translated to 
form a polyprotein from the viral genome´s single open reading frame (ORF). 
Polyprotein is cleaved by virus-encoded proteases to produce the final virus 
proteins. RNA synthesis occurs in special replication organelles or vesicles, where 
the (+)ssRNA genome is copied through a negative strand RNA intermediate, which 
is then used as a template for new viral genomes. Double-stranded (dsRNA) 
intermediate molecules are also formed at this stage. The final steps of replication 
cycle include packaging the newly formed RNA inside the viral capsid to form new 
infectious particles and the release of these particles outside the host cell. Fig. 3 
details the different steps of the replication cycle. Viral proteases 2Apro and 3Cpro are 
the main proteases responsible for the cleavages of the polyprotein into structural 
and nonstructural proteins that eventually form the capsid structure. The cleavage 
processes of 2Apro and 3Cpro are not limited to the viral protein processing only, but 
they also cleave several other cellular factors and protein targets to support virus 
reproduction and also to optimize the environment for viral proliferation. (8,9) 
Different enterovirus types recognize different cellular receptor(s). The capsid 
proteins are responsible for the binding to a cell receptor, which then initiates the 
infection. Many enteroviruses use similar receptor molecules that belong to the 
immunoglobulin superfamily (IgSF). IgSF-like receptors include for example 
poliovirus receptor (PVR or CD155) for polioviruses (PVs), coxsackie-adenovirus 
receptor (CAR) for coxsackie B viruses (CV-Bs) and intercellular adhesion molecule-
1 (ICAM-1) that is used by coxsackievirus A21 (CV-A21) and many rhinoviruses. The 
extracellular regions of IgSF receptors have two to five N-terminal immunoglobulin-
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like domains, of which the outermost domain, D1, is involved in the binding with the 
conserved amino acid residues of a special region called “the canyon” of the virus 
capsid. Some enteroviruses may also use non-IgSF cell surface receptors. These 
receptors include the decay-accelerating factor (DAF or CD55) and a number of 
integrins, which are used by certain echoviruses and CVBs, and heparan sulfate that 
is used by many hand foot and mouth disease (HFMD) viruses, such as CV-A16 and 
EV-A71 (10). 
 
Figure 3.  Enterovirus replication cycle: 1. Binding of virus to receptor e.g.. CAR, DAF. 2. 
Internalization of the virus. 3. Release of RNA genome from the virion. 4. Translation into 
polyprotein 5. Proteolytic processing by viral proteases into viral proteins. 6. Replication of the RNA 
genome via a dsRNA intermediate mediated by the nonstructural proteins in replication organelles 
or vesicles. 7. Newly synthesized positive-stranded RNA molecules either enter another round of 
replication (orange arrow) or are packaged into the viral capsid proteins to form new infectious 
particles. 8. Release of new infectious particles by cell lysis or non-lytic mechanisms. Modified from 
van der linden et al 2015 Viruses. (8) 
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2.1.2 Enterovirus diseases 
Enteroviruses are very common around the world, usually causing mild 
asymptomatic infections. Transmission happens via fecal-oral or respiratory routes. 
Enterovirus circulation follows a seasonal pattern in temperate climates, where 
enteroviruses are found during the summer and early months of the fall. In tropical 
areas, however, enteroviruses can be found constantly throughout the year, or they 
are associated with the rainy season (9,11). 
Regardless of the fact that most enteroviral infections are mild, infection can also 
lead to acute illnesses, such as herpangina and HFMD (12). Acute severe diseases 
result from virus spreading from the primary replication site to other target organs. 
These severe diseases include acute flaccid paralysis, pericarditis, myocarditis, 
meningitis and encephalitis (9,13,14). Young age and male gender increase the risk 
of severe diseases (9).  Enteroviruses have also been linked to certain chronic 
diseases, such as chronic dilated cardiomyopathy (15) and T1D (16-19). The role of 
enteroviruses in T1D is discussed further in Chapter 2.6. 
2.2 Diagnosis of enterovirus infections 
Reliable diagnosis of enterovirus infection requires laboratory methods to detect 
the virus or virus-induced immune responses. Several assays are available. The 
sensitivity to diagnose enterovirus infections depends on the selection of the assay 
and collection of optimal types of samples. For example, acute infection can be 
diagnosed by detecting the virus directly from clinical samples while serological 
assays are used to detect recent infection and immunity. During acute infection, 
virus titers are usually high in stools and nasopharyngeal mucosa but the virus can 
also be detected in cerebrospinal fluid during central nervous system infection and 
in the skin blisters during HFMD. Virus can also be detected in tissue samples, e.g. 
in brain tissue during acute encephalitis and in myocardium during acute 
myocarditis. Thus, enteroviruses can be detected from nasal and throat swabs, 
cerebrospinal fluid, stool, tissues and blood samples. Different diagnostic methods 
are described below.     
2.2.1 Virus Isolation 
Enteroviruses can be isolated from different sample types (i.e. stool, cerebrospinal 
fluid, nasopharyngeal aspiration, tissue, blood). Isolation requires sterile cell culture 
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conditions and cell lines that support the virus replication. Samples are incubated in 
cells and observed regularly to detect possible virus replication either by visual 
inspection (monitoring cell death or formation of cytopathic effect) or by using 
enterovirus-specific antibodies and immunofluorescence microscopy. Reliable 
diagnosis requires confirmation of the presence of enterovirus by preventing virus 
replication using enterovirus specific hyperimmune sera, detecting enteroviral 
proteins using immunostaining or detecting viral nucleic acids using RT-PCR. The 
advantage of virus isolation is that the isolated virus becomes available for further 
studies. The main limitations include the facts that the assay is labor-intensive, the 
virus needs to retain its infectivity in the original sample and many enteroviruses do 
not replicate efficiently in commonly used cell lines. (20) Due to these limitations 
virus isolation has largely been replaced by RT-PCR based assays and is currently 
only rarely used in routine diagnostic laboratories. 
2.2.2 RT-PCR 
Currently, the most common method used to detect enteroviruses in clinical virus 
laboratories is reverse transcription PCR (RT-PCR) (21,22). In RT-PCR, viral RNA is 
first transcribed into complementary DNA (cDNA), which in turn is subsequently 
used as a template for the PCR reaction (23). This principle is the basis of 
amplification of virus genome using virus specific primers, providing high sensitivity 
and specificity for the assay. Various modifications of RT-PCR exist. Traditional assay 
includes 30-40 cycles of PCR amplification followed by the detection of enterovirus-
specific PCR products by inspecting the bands of right molecular size in gel 
electrophoresis or by detecting enterovirus specific sequences using 
oligonucleotide probes or sequencing.  In nested and semi-nested PCR, the amplicon 
of the initial PCR is amplified using another primer pair. During the past decades, 
real-time PCR technologies have revolutionized the detection of enteroviruses. 
These technologies are based on labelled probes (such as TaqMan), which emit 
fluorescing signal in correlation to the amount of PCR amplicons in the PCR reaction. 
Advantage of this method compared to gel electrophoresis is that the probe detects 
the amplicons according to sequence, which confirms that the detection is specific 
for the target of interest (24). These technologies allow the quantification of the 
viral RNA using fluorescent labeling and continuous monitoring of amplification as 
PCR reaction progresses. This makes it possible to quantify the number of copies of 
viral genome that are present in the sample. Accurate quantification requires 
standards with known amount of viral genome. Due to the quantitative nature, this 
kind of assay is called quantitative PCR (qPCR). The primers that are used to reverse 
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transcribe and amplify enterovirus RNA, influence the sensitivity of RT-PCR. 
Enterovirus 5’UTR is highly conserved between different enterovirus types, and 
primers targeting this region enable a sensitive, specific and effective detection of a 
wide range of different enterovirus types/species. For this reason, 5’UTR RT-qPCR is 
also recommended as a primary assay for enterovirus detection (25). Amplification 
of viral genome offers also possibilities for molecular typing of detected 
enteroviruses by sequencing the PCR products. Depending of the sequenced 
genome region this method can be used to classify enteroviruses in different genetic 
clusters ranging from two clusters (conserved 5’UTR) to the individual types (VP1 
coding region corresponding to traditional serotype of the virus) (26-28). 
2.2.3 Immunohistochemistry 
Antibody-based methods can be used for the detection of enteroviruses in cell and 
tissue samples, for example using immunohistochemistry (IHC) (29-31). One major 
advantage of IHC is the ability to visualize and localize the virus antigen directly 
within cells and tissues. IHC is based on specific binding of specific antibodies to the 
target antigen and visualization of this binding by labelling the bound antibody. 
Enzyme- and fluorophore-mediated chromogenic and fluorescent detections, 
respectively, are the most popular methods. In chromogenic IHC, an enzyme label 
(such as alkaline phosphatase (AP) and horseradish peroxidase (HRP)) is allowed to 
react with its substrate (such as 3,3’-diaminobenzidine (DAB)) to yield an intensely 
stained precipitate. In immunofluorescence (IF) detection, organic fluorophores or 
fluorescent dyes are conjugated to the primary or secondary antibody (32).  
The steps and reagents included in IHC depend on the sample type, target in 
question and the nature of target-specific antibody. For paraffin sections 
deparaffinization and subsequent rehydration is necessary. Most antigens and 
antibodies require an antigen retrieval method, which renatures the proteins to 
their pre-fixation conformation. Primary antibodies can be directly labeled with a 
dye (direct method), or a secondary antibody conjugated with the label can be used 
for the detection (indirect method). Sample staining can be performed manually or 
by using an automated system, and viewed with a brightfield or fluorescence 
microscope, depending on the staining methodology applied (chromogenic vs. 
fluorescing label) (32). 
Staining of the samples is usually performed on microscope slides to which thin 
tissue and/or cell samples have been placed (works for both fixed samples and 
frozen tissue sections). Cell or tissue microarrays (CMAs or TMAs) are beneficial in 
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terms of time and reagents used as several samples can be co-stained. These 
microarrays can be made by drilling small cylindrical punches from donor paraffin 
blocks, using a syringe needle, and placing them to a recipient paraffin block. (33) 
Currently, the commercially available mouse monoclonal antibody clone 5D8/1 
from Dako (M7064, Agilent) is the most widely applied for the detection of 
enterovirus proteins by IHC. This antibody recognizes an epitope from the N-
terminal region of the capsid VP1 protein and can be used for formalin-fixed, 
paraffin-embedded (FFPE) samples (34,35). Clone 5D8/1 recognizes a wide range of 
enteroviruses from species B, such as CV-Bs and echoviruses 3, 6, 9, 11 and 30 (36). 
However, some echoviruses, such as echovirus 2, 8 and 19, and EV68-71 (37) are not 
recognized. Potential cross-reactivity of clone 5D8/1 with host proteins has recently 
been discussed (38,39). However, it has been shown that cross-reactivity is not an 
issue when the antibody is used in optimized conditions (40). Other commercially 
available enterovirus antibodies are also available, such as ready-to-use enterovirus 
screening-set (Ref. 3465, Light Diagnostics, EMD Millipore Corporation), which 
contains six different monoclonal antibodies against different enterovirus groups. 
Additional broad-recognizing enterovirus antibodies would be beneficial to verify 
the enterovirus findings obtained with clone 5D8/1. However, the availability of 
such antibodies is limited, although attempts have been made for their production 
(39,41,42).  
2.2.4  In situ hybridization 
In situ hybridization (ISH) can be used to detect and localize viral RNA in infected 
tissues. This technique is mainly used for FFPE samples. ISH is based on the use of 
labelled probes that bind specifically to the target RNA or DNA during the 
hybridization step (43). ISH is a demanding method, which includes several steps 
and is more sensitive to errors compared to IHC, in which antibodies are used. 
Traditional ISH techniques include radioisotope-labeled probes, but nowadays non-
isotopic ISH applications are mostly used. However, they lack the sensitivity and 
specificity required to measure low-abundance biomarkers reliably (44). Novel 
commercially available ISH techniques have recently arrived on the market, such as 
QuantiGene® ViewRNA by Invitrogen (previously Affymetrix) and RNAscope by ACD 
Biosystems (45). The workflow in these novel ISH techniques includes four main 
steps: sample preparation, target hybridization, signal amplification and detection 
(Fig. 4). These techniques promise even single molecule detection of multiple 
targets in single cells in optimal conditions, due to a fluorescent ISH and a sequential 
branched DNA amplification technique. The techniques also enable a customized 
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probe design for the target in question and parallel detection of multiple targets by 
using a unique label (color) for each target. Different kits are available for cell and 
tissue preparations, and currently one or two targets can be stained and visualized 
simultaneously in tissue samples, whereas cell preparations offer simultaneous 
visualization of up to four different RNA targets (43,45). 
 
 
Figure 4.  Schematic drawing on the workflow of novel ISH tecniques that base on branched DNA 
technology and subsequent amplification steps. In this example, two different targets are detected. 
In step 1 cells or tissues are fixed and permeabilized to allow the designed probe access its target. 
In the drawing, the blue and green colors represent different target probes. In step 2, target RNA-
specific oligonucleotide probes (Z) are hybridized in pairs (ZZ) to multiple RNA targets. Only ZZ 
pairs will produce a signal in the subsequent amplifications steps. In step 3, signal is amplified with 
specific amplifier molecules, each specific for their target probe. Each label probe is conjugated to 
a different fluorophore or enzyme. In step 4, signals can be detected using a brightfield or 
fluorescence microscope, depending on the assay. (Modified from Wang et al. (2012) J. Molec. 
Diag. (45)) 
2.2.5 Other enterovirus detection methods 
Next generation sequencing (NGS) methods allow an unbiased detection of any 
virus, including enteroviruses. NGS techniques produce a large amount of sequence 
data, increasing the likelihood of finding a small amount of virus sequence from the 
sample. The challenges of NGS techniques include the capacity of managing the 
computational data and cost of processing the samples (46), though the costs have 
come down substantially during the past few years. In addition, the sensitivity of 
NGS in virus detection is usually lower compared to specific PCR. 
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Proteomics has not been widely used for the detection of enteroviruses. In 
proteomics, proteins are studied on a large scale in biological systems. Studying 
proteins that are produced by the cell or that are present in a cell is useful, since not 
all mRNA is translated into protein; thus, simply studying the genomic contents 
would not tell the whole story about proteins present in the cell. Proteomics can 
also overcome and identify post-translational modifications of proteins that are 
critical to the protein’s function. Therefore, proteomics confirms the presence and 
nature of the protein, and provide a direct measure of the quantity of the protein 
present. Numerous sample types, such as tissue, cell lines, enriched cell organelles 
and laser-captured micro-dissected cell populations, can be analyzed. Several 
proteomics approaches already exist; recently, these techniques have evolved 
enormously, leading to high sensitivity and specificity when digesting specific 
peptides from the samples. Regardless of these advantages, proteomics 
technologies are new and expensive and not yet routinely applied in enterovirus 
diagnostics. One of the most sensitive technologies is a liquid chromatography 
multiple reaction monitoring mass spectrometry (LC/MRM/MS/MS) on a triple 
quadruple (QqQ) mass spectrometer. It provides a rapid, sensitive, and specific 
identification and quantitation of targeted compounds in complex samples. The 
technological basis of this system in a QqQ mass spectrometer provides the 
capability to identify an ion of interest (Q1 m/z), followed by the ability to segregate 
and fragment that precursor ion in the collision-induced chamber (in Q2). It also 
enables the identification of the ion of interest from the fragmented precursor ion 
(Q3 m/z), and only detects ions with this exact transition (47,48). 
2.2.6 Detection of enterovirus-specific serum antibodies 
Enterovirus infection can be diagnosed by detecting enterovirus-specific antibodies 
from serum or other body fluids. Detection of enterovirus-specific IgM can be used 
to diagnose acute or recent infection from a single serum sample. Increases in IgG 
titers can be used to diagnose infection using paired sera (acute and convalescence 
serum). The most widely used method is enzyme-linked immunosorbent assay 
(ELISA). It is a fairly simple and low cost technique that can be used to detect 
antibodies against enteroviruses in different immunoglobulin classes. The 
antibodies that bind to certain enterovirus antigen in ELISA are not specific for that 
enterovirus type but represent heterotypic antibodies that cross-react widely 
between different enteroviruses (49). 
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Enterovirus infection induces antibodies that neutralize the infectivity of the virus. 
Acute infection can be diagnosed by showing an increase in neutralizing antibody 
titers between paired serum samples. These antibodies stay elevated for a long time 
after the infection and provide protection against reinfection. They are type-specific 
and can be used to identify the type of enterovirus causing the infection. Therefore, 
hyperimmune animal sera containing high titers of neutralizing antibodies against 
specific enteroviruses have been used to identify the type of enteroviruses detected 
by virus isolation in cell cultures. Presence of neutralizing antibodies in a single 
sample reflects the infection history of an individual, although in some cases also 
transient antibody responses can occur, especially if the infection has been 
associated with a low virus titer (50). Serum is considered seropositive if it can 
inhibit a virus-induced cytopathic effect or the formation of plaques in cultured cells 
(51). Thus, the assay requires sterile cell culture work and is expensive and labor-
intensive. Therefore, it is not used in routine diagnostics. 
2.3 Immune response against enteroviruses 
Mammalian immune system is remarkably complex, enabling efficient recognition 
of invading pathogens and impaired host proteins that threaten the host 
homeostasis. Generally, the immune system is divided into two systems based on 
their functions in host defense: innate and adaptive immunity. While innate 
immunity provides robust, immediate and non-specific immune responses through 
i.e. complement activation and pathogen engulfment (52), adaptive immunity is 
organized around T and B lymphocytes that orchestrate diverse repertoire of 
antigen-specific recognition receptors and long-lived immunological memory 
against reinfection (52). Despite being timely, temporally and mechanistically 
separate systems, innate and adaptive immune system have complex interactions 
that regulate their function.  
When an enterovirus encounters the body, it first infects cells in intestinal mucosa 
or upper respiratory tract and consequently spreads to local lymph nodes 
underneath the mucosa. The virus may also spread to secondary organs, such as the 
heart, pancreas and central nervous system (CNS), although the mechanism is not 
fully established. The first rapid defense against enterovirus infection is triggered 
when pathogen recognition receptors (PRRs), such as Toll-like receptors (TLRs) and 
retinoic acid-inducible gene (RIG-I)-like receptors, recognize enterovirus-specific 
pathogen-associated molecular patterns (PAMPs) (53). Enterovirus-specific PAMPs 
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include ssRNA and dsRNA. Enterovirus that releases its ssRNA genome in the cells 
becomes recognized by TLR7 and TLR8 molecules. dsRNA is formed as a replication 
intermediate when the virus starts replicating and is recognized by intracellular 
vesicle-associated TLR3 or by the sensor melanoma differentiation-associated gene 
5 (MDA5) (54). This leads to synthesis of cytokines, like type I interferons (IFN), in 
infected cells, with strong antiviral activity creating an antiviral state in the 
surrounding cells by the expression of proteins with antiviral activity (55). For 
example, the lack of MDA5 in a knockout mouse model leads to deficient type I IFN 
production and increased early mortality in CV-B infection (56). Overall, genes that 
interfere with virus replication prevent spread to neighboring cells and activate the 
adaptive immune response (57). 
Innate immune responses also regulate adaptive immune responses. In fact, 
antigen-presenting cells (APCs) are also activated by PAMPs after which they 
present virus antigens to antigen-specific effector cells of the adaptive immune 
system. The adaptive B cell response produces and controls the production of 
antibodies against the infective virus during acute infection, and protects against 
reinfections by the same virus type (55,58). These antibodies inactivate enterovirus 
by neutralization and opsonization or commence the destruction of the infected 
cells by activating the complement (58). Antibody response seems to be a 
particularly important factor in the eradication of enterovirus infection and in the 
immunity against re-infections by the same serotype (presence of neutralizing 
antibodies correlate with protection) (59), while the role of T cell mediated immune 
responses is less well characterized. However, at least CD4+ T cells recognize virus 
antigens that are bound to class II HLA molecules and can facilitate wide range of 
immune responses including the production of antibodies by B lymphocytes (Th2 
type cells) and  production of cytokines and chemokines (Th1 and Th17 type cells) 
that can mediate inflammation. CD8+ T cells, in turn, are activated by virus antigens 
presented by HLA class I molecules and can have direct cytotoxic effects on virus-
infected cells (60).  
Enteroviruses induce strong cell-mediated immune responses. However, their role 
in the eradication of the virus and in immune protection is less characterized 
compared to that of antibody responses. For example, memory T cells cross-react 
between different enterovirus types, generating anamnestic responses that speed 
up the eradication of the virus (55). Enteroviruses can cause a severe and/or chronic 
infection in immunocompromised and immunosuppressed individuals, or neonates 
who have an immature immune system (61). Humoral immunodeficiencies increase 
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the susceptibility to enteroviruses more than T cell deficiencies suggesting an 
important role of neutralizing antibodies in immune defense against enteroviruses 
(62). Such severe infections may lead to encephalitis or myocarditis and, in extreme 
cases, to death.  
2.4 Pathogenesis of type 1 diabetes 
Type 1 diabetes (T1D) is a life-long disease in which insulin-producing pancreatic 
beta cells are selectively impaired or destroyed. Historically T1D was referred to as 
juvenile diabetes due to the high incidence of the disease among children. This term 
is no longer recommended, since it is known that T1D can occur at any age, and 
about 50% of the cases are diagnosed at over 30 years of age (63). The incidence 
and prevalence of T1D varies substantially: Finland leads the statistics with the 
incidence of over 60 (>60 cases per 100 000 children each year). The prevalence of 
T1D is generally higher in countries with European ancestry; however, the disease 
incidence has wide variations even in neighboring areas in Europe and North- 
America (64). The incidence of T1D is very low (0.1 cases per 100 000 people each 
year) in countries like China, India and Venezuela (65). The incidence of T1D has 
been increasing during the past decades, although fluctuation or even plateau 
phases have also been observed (66). It is unclear, however, what the reason is for 
the ongoing increase, but changes in nutrition, virus infections, hygiene and gut 
microbiome have been given much attention (65,67)  
At cellular level, the process leading to T1D is associated with an infiltration of the 
immune system cells into the islets of Langerhans, where insulin-producing cells are 
located. Genetic predisposition is a risk factor, but genes only partly explain the T1D 
incidence rates. This is supported by the fact that less than 10% of the children 
carrying the HLA risk genes will develop T1D (68), and studies performed on 
monozygotic twins have also shown less than 35% concordance rate for T1D (69,70), 
therefore indicating additional input of non-genetic factors. Consequently, other 
factors besides genetic factors trigger disease progression. It is common in many 
autoimmune diseases that both genes and biological factors make the individual 
susceptible for disease progress, and this occurs during the lifespan. Presently, it is 
well accepted that T1D is a disease that may have multiple origins, and 
environmental factors such as nutrition, vitamins, toxins or viral infections have 
been proposed to play a significant role in the pathogenesis of T1D. Specifically, 
enteroviruses are currently considered the major triggers of T1D development (see 
chapter 2.6).  
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2.4.1 Autoimmunity 
In T1D, pancreatic beta cells are destroyed through a process characterized by an 
inflammation of the pancreatic islets and the appearance of autoantibodies that 
bind to beta cell autoantigens. Despite the fact that the exact mechanism leading to 
this destruction remains unclear, it is evident that normal immune system reacts 
against beta cell autoantigens. The disease progression is usually relatively slow and 
initiated long before the clinical T1D is diagnosed. The appearance of autoantibodies 
that target pancreatic islet antigens characterizes the initiation of the disease 
process. Autoantibodies against insulin (IAA), insulinoma-associated protein 2 (IA-
2A), glutamic acid decarboxylase (GADA) or zinc transporter 8 (ZnT8A) can be found 
from peripheral blood during this prediabetic phase (71). All these antigens are 
localized in secretory granules of the beta cells (72), and all except insulin can also 
be found in some other cells and tissues. The time from seroconversion to 
autoantibody-positivity and subsequent development to T1D may take from a few 
weeks to several years. However, not all autoantibody-positive individuals will 
develop T1D. The risk for developing the disease generally increases with the 
number of autoantibodies detected, and the majority of children who are positive 
for two or more of these autoantibodies will develop T1D (73). 
2.4.2 Genetics 
The first T1D genetic susceptibility locus, the human leukocyte antigen (HLA) on 
chromosome 6p21 (Fig. 5), was found in the 1970s. Before the genome-wide 
association studies (GWAS) five other loci were established to be associated with 
T1D. With the development of high-throughput, single nucleotide polymorphism 
(SNP) genotyping arrays and GWAS systems, the number of T1D susceptibility genes 
has risen to almost 60 (74). Recent data have shown, for instance, that SNPs in genes 
that are involved in the immune response against viruses, such as MDA5 and 
tyrosine kinase 2 (TYK2), are risk factors for T1D (75-79). The HLA class II genes 
account for approximately half of the genetic risk for T1D (80) despite the high 
number of candidate genes. The polymorphisms in HLA class II genes encoding HLA-
DQ and HLA-DR (Fig. 5) are linked to the highest T1D risk. Such haplotypes include 
HLA-DR3-DQ2 and HLA-DR4-DQ8, and the risk is the highest for the heterozygote 
formed by these two haplotypes. Some haplotypes, such as DR2-associated 
haplotypes, have in contrast been shown to protect from the disease (80). The HLA 
genes encode highly polymorphic proteins, which are essential to self- versus non-
self-immune recognition. The HLA class II molecules are expressed in APCs, such as 
 26 
dendritic cells and macrophages, which introduce the pathogen antigens to CD4+ T 
cells. This interaction promotes inflammation reaction via secreted cytokines. 
Conversely to HLA class II, the HLA class I molecules are expressed in virtually all 
nucleated cells, where they function by presenting intracellular antigens to CD8+ T 
cells. HLA class III genes encode proteins that are involved in the complement 
activation pathways, such as C2, factor B (Bf) and C4. Genes for the heat shock 
proteins and tumor necrosis factor (TNF) are also located in the HLA class III region. 
The physiological role of most of the HLA class III genes is yet to be determined, but 
some genes in this region are already linked to certain diseases, including T1D and 
Alzheimer’s disease (80,81).  
 
 
Figure 5.   Gene map of the HLA region on human chromosome 6. HLA region, with class II, class III 
and class I genes, is located in the short arm of chromosome 6. HLA class I molecules control 
CD8+ cytotoxic T cell function and mediate immune responses against ‘endogenous’ antigens and 
virally infected targets, whereas HLA class II molecules are involved in the presentation of 
‘exogenous’ antigens to CD4+ helper T cells. HLA class III region contains many genes encoding 
proteins that are unrelated to cell-mediated immunity, yet modulate or regulate immune responses 
by unknown manner. These include TNF, heat shock proteins and complement proteins (C2, Bf 
and C4). Adapted from Expert Reviews in Molecular Medicine C 2003 Cambridge University Press. 
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2.4.3 Pancreas pathology 
The human pancreas is located in the retroperitoneal space of the abdominal cavity 
behind the stomach in close proximity to the duodenum and spleen (Fig. 6). The 
pancreas is a multifunctional organ consisting of acinar cells that produce digestive 
enzymes in the exocrine pancreas and glucose homeostasis hormone-producing 
cells in the endocrine pancreas, i.e., in the islets of Langerhans. The exocrine 
compartment comprises 98%, and the endocrine compartment comprises only 
approximately 2% of the whole pancreas.  
 
Figure 6.  The human pancreas and its surroundings. Pancreas is located in close proximity to small 
intestine and spleen. Exocrine pancreas comprises acinar cells that produce and secrete digestive 
enzymes. The endocrine pancreas comprises Islets of Langerhans or pancreatic islets that are 
distributed throughout the pancreas. In the insert, a representative image of an islet immunostained 
for insulin. Adapted and modified from Anatomy and Physiology, an OpenStax resource at 
http://philschatz.com/anatomy-book/contents/m46685.html.  
 
The endocrine cells, which are clustered into ‘islets’, comprise five different 
hormone-producing cell types: alpha cells that secrete glucagon, beta cells that 
secrete insulin, delta cells that secrete somatostatin, PP cells that secrete pancreatic 
polypeptide and epsilon cells that secrete ghrelin (Fig. 7) (82). Islets are distributed 
throughout the whole pancreas, contain approximately 1500 cells each, and are 
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150-300 μm in diameter (83). A vast vascular network of small capillaries runs 
through islets, which are also innervated by the symphathetic, parasymphatetic and 
sensory nervous system (84). The larger islets contain afferent arterioles, which 
branch from intralobular arteries in the exocrine tissue (85). 
 
Figure 7.  Schematic drawing of an Islet of Langerhans. The endocrine compartment of pancreas 
comprises only about 2% of the whole pancreas and is composed of Islets of Langerhans. In these 
islets, five different cell types produce five different hormones, insulin-producing beta cells being 
the most abundant. Veins and small capillaries are also abundantly present. Islets also contain 
afferent arterioles (not shown) which supply and regulate the blood flow (85). 
 
T1D results from the specific destruction of pancreatic beta cells, which is, according 
to the current understanding, preceded by an inflammatory infiltrate targeting the 
islets. This phenomenon is known as “insulitis”, which consists predominantly of T 
cells dominated by CD8+ lymphocytes but also CD4+ lymphocytes, B lymphocytes 
and macrophages (86). Insulitis is defined as an event where at least three islets in 
a pancreatic section having 15 or more CD45+ lymphocytes infiltrate the islet (87). 
CD45 is a common leucocyte marker that recognizes both T and B cells. Insulitis 
lesion mainly affects islets with residual beta cells but it has occasionally also been 
observed in pseudoatrophic (insulin-negative) islets (88,89). In recent studies, 
different insulitic profiles have been identified in patients diagnosed with T1D at 
younger age and for patients diagnosed at adolescence or an older age. These 
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profiles are categorized according to the number of CD20+ lymphocytes in the 
infiltrate or, more specifically, according to the ratio of CD20+:CD4+ lymphocytes. A 
patient is categorized as CD20Hi if this ratio is >1.0 and as CD20Lo if the ratio is <1.0. 
Patients diagnosed before age seven always express the CD20Hi profile and have a 
more aggressive form of beta cell loss, whereas patients diagnosed at or above the 
age of 13 always display CD20Lo profile, with less aggressive loss of beta cells (90). 
The lymphocyte infiltration to islets is substantially rarer than the infiltration 
occurring in other autoimmune diseases, since only a small fraction of islets is 
affected by this phenomenon, and the number of infiltrating lymphocytes is quite 
small. Another early phenomenon of initiated autoimmune process is class I HLA 
(human leucocyte antigen or major histocompatibility complex, MHC) 
hyperexpression of the islets (see chapter 2.6.5).  
2.5 Mechanism of virus-induced autoimmunity 
The prevalence of many autoimmune diseases is increasing worldwide, but their 
etiology often remains to be determined. It is evident that environmental factors 
strongly influence the initiation and development of these diseases, although 
genetic predisposition plays an important role. Viral infections have been identified 
among the most potential autoimmunity triggers.  
Molecular mimicry is one of the suggested mechanisms of autoimmunity. Viruses 
may contain peptides that are similar in their amino acid sequence or structure to 
self-antigens. It is hypothesized that when immune cells are activated in response 
to the virus, they may also recognize self-antigens and, thus, initiate an immune 
response that finally leads to destruction of these self-antigens, leading to 
autoimmunity (91). On the other hand, epitope spreading can occur due to collateral 
damage and active release of self-antigens caused by the immune response against 
the virus. APCs process and present viral and self-antigens to T cells, which in turn 
initiates an autoimmune process. Bystander activation of autoreactive T cells has 
also been proposed as a reason for inflammation (92). During bystander activation, 
HLA I molecules present viral antigens to virus-specific T cells that migrate to areas 
of infection. HLA I is a heterodimer, consisting of type I integral membrane 
glycoprotein heavy chain (HC) complex in association with soluble β2-microglobulin 
(β2M) (Fig. 8 A). All nucleated cells express HLA I molecules on the cell surface, where 
they present peptide fragments derived from the degradation of intracellular or 
viral proteins. Peptides are loaded in the peptide-binding groove of the HLA I – β2M 
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complex on the cell surface, where they are constantly monitored by CD8+ cytotoxic 
T lymphocytes (CTLs). These CTLs mount an immune response upon the recognition 
of the peptide by T cell receptor (TCR), which kills the infected cells (93) (Fig. 8 B). 
Therefore, when CTLs and macrophages release cytokines at the inflammation site, 
the process may also lead to bystander killing of the uninfected neighboring cells. 
Persistent virus infections, where viral proteins are expressed at very low levels 
without cell lysis, may also lead to immune-mediated injury, since the viral antigen 
is constantly present sustaining the immune response. Persistent viral infections 
have been linked to at least myocarditis, multiple sclerosis and T1D (53). 
 
Figure 8.  Structure and location of the HLA I complex. A) The heterodimeric structure of HLA I (MHC 
I) consists of type I transmembrane heavy chain (subunits α1-α3) and soluble β2 microglobulin 
(β2m). Subunits α1 and α2 form the peptide binding groove of the complex. B) Intracellular 
antigens, such as virus proteins, are processed into peptides by the immunoproteasome, after 
which the peptides are transported into the endoplasmic reticulum (ER), where they are loaded 
into the groove of the HLA class I complex.  HLA class I complexes present antigens on the cell 
surface to CD8+ T cells. (Modified from Kobayashi, KS 2012 Nature rev. (94)) 
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2.6 Enterovirus – type 1 diabetes association 
2.6.1 Epidemiological studies 
The pathogenesis of T1D has been associated with viral infections since the 1960s. 
Decades of research have provided epidemiological evidence for enterovirus 
association to the disease, although potential association has also been proposed 
for rotavirus and some other viruses (95,96). Gamble and Taylor, were the first to 
discovered a similar seasonal peaking pattern for enteroviruses and the onset of 
T1D (97). They proposed for the first time that the seasonal variation of T1D (that 
peaks during fall months) resembles that of enterovirus infections and that these 
viruses may, thus, play a role in the pathogenesis of T1D. Since then, the seasonal 
connection has been widely studied (98). Antibodies against enteroviruses have 
been measured from T1D patients and non-diabetic controls in several studies. In 
some of these studies, but not all, a risk association was detected (99-104). 
Measurement of neutralizing antibodies from European populations have indicated 
that CV-B1 and other CV-Bs are associated with the risk of T1D (51,59).  
 
Table 1.  Summary of retrospective case-control studies showing a positive association between 
enteroviral RNA in the blood and T1D in different countries. 
 
Country T1D cases Controls Reference 
N Pos N Pos 
UK 14 64% 45 4% (105) 
UK 110 27% 182 5% (106) 
France 23 42% 27 0% (107) 
France 56 38% 37 0% (108) 
Sweden 24 50% 24 0% (109) 
Australia 206 30% 160 4% (49) 
Japan 61 38% 58 3% (110) 
Netherlands 10 2% 20 0% (111) 
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Many other studies also associate enteroviruses to T1D or T1D-related 
autoimmunity (112-114). Table 1 summarizes retrospective case-control studies 
performed in different countries. In these studies a positive association between 
enteroviruses and T1D was found. 
2.6.2 Prospective studies  
Prospective studies, in which initially healthy individuals are followed up, have 
provided evidence that link enteroviral infection to T1D. Finland was the first 
country where such studies were conducted, and they showed that enteroviruses 
were more common in children who progressed to T1D than in healthy control 
children (104). This observation was supported by other studies (112,115-123). 
Prospective cohort studies are important for identifying the environmental 
determinants involved in the initiation of the beta cell destruction. A large number 
of children are followed in such studies until some of them develop T1D. The largest 
prospective studies carried out so far include The Finnish Diabetes Prediction and 
Prevention (DIPP) study (115,121) that has been recruiting children since 1994, The 
Environmental Determinants of Diabetes in the Young (TEDDY) study (96), which has 
recruited children in the US and Europe, The Diabetes Autoimmunity Study in the 
Young (DAISY) (102,123) in the US, the Environmental Triggers of Type 1 Diabetes 
(MIDIA) (124) in Norway and the BABYDIAB (125) in Germany. Collectively, the 
results from these studies have shown an association between enterovirus 
infections and initiation of beta cell-damaging process by detecting viruses from 
serial blood or stool samples and by analyzing antibodies from serum 
(22,115,117,123). Prospective studies have also shown that among all different 
enterovirus types, CV-Bs are most often linked with T1D (113,126,127). These 
prospective studies can provide significant insight into the temporal relationships 
between enterovirus infections and initiation and the progression of the beta cell-
damaging process.  
2.6.3 Enterovirus in tissues of type 1 diabetic patients 
Coxsackievirus B4 (CV-B4) was the first enterovirus to be isolated from the pancreas 
of T1D patients in 1979 (128,129). In follow-up study, it was inoculated into a mouse 
in which it caused diabetes (128). Later on CV-B4 was also isolated from islets of a 
patient suffering from T1D. This virus was able to replicate in the islets of non-
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diabetic controls in vitro, impairing glucose-stimulated insulin secretion in infected 
islets of T1D patients (129). So far, enteroviruses have been reported in pancreatic 
islets of T1D subjects more commonly than in non-diabetic controls (30,129-131). 
For example, enterovirus VP1 protein was found in the pancreatic islets of six 
recent-onset T1D patients of the DiViD study (130). Enterovirus genome was also 
detected in the isolated pancreatic islets (culture supernatants) of four of these 
patients, while all the controls were negative. In addition, studies report that the 
small intestine of T1D patients is more frequently positive for enteroviruses 
compared to non-diabetic controls (29,132).  
2.6.4 Role of pancreas studies in type 1 diabetes research  
Pancreas is a multicellular organelle, and therefore it is important to establish which 
cell types are infected by enteroviruses. IHC studies have shown that enterovirus 
proteins are mainly detected in the pancreatic islets, and almost exclusively in 
insulin-producing beta cells (133).  
Due to the difficult location of the pancreas, pancreatic samples are not usually 
available from living T1D patients. Instead, most of the pancreas samples analyzed 
from T1D patients have been obtained from either brain-dead organ donors or in 
routine autopsies. Post-mortem samples are not ideal, since they may have been 
affected by post-mortem changes and conditions that may have an effect on several 
markers that have been analyzed in the samples (134). The availability of pancreatic 
biopsies from living patients is scarce. Altogether, large tissue collections, such as 
the archival collection of postmortem samples from the UK (135), the nPOD 
(network for Pancreatic Organ Donors with Diabetes, USA) (136) and DiViD (The 
Diabetes Virus Detection study, Norway) (137), have made pancreas and other 
tissue samples available for research purposes, enabling international studies on the 
complex mechanisms involved in the T1D pathogenesis. DiViD is a unique study from 
Norway, where pancreatic biopsies were taken from six recent onset adult T1D 
patients. This study has given the unique possibility to study pancreatic samples 
soon after the actual start of the disease (3 to 9 weeks after onset), which provides 
insight into the pancreatic immunopathology at the time of commencement of the 
disease. The nPOD and UK cohorts (135,136) offer a great opportunity for pancreatic 
studies and have so far revealed new data on many aspects of T1D, such as the T1D 
–enterovirus association (30,130,131,138-140). They have also confirmed some of 
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the previous findings related to T1D, such as the presence or phenomenon of 
insulitis and the general pancreas pathology in T1D patients (90,141-143). 
2.6.5 Immunological protein markers of virus infection 
Several type I IFN-stimulated markers, or indirect virus-related markers, are 
associated with T1D. Type I IFNs are produced upon viral infection, replication, 
and/or the introduction of double-stranded RNA (Fig. 9). They trigger antiviral 
activity and induce maturation of effector T cells (144). For example, the cytokine 
IFN-α, a member of the type I IFN family, has been found to be expressed in the 
islets of T1D patients (145,146). Followed by viral infection, type I IFNs are secreted 
to neighboring cells and function by inducing different IFN-stimulated genes (ISGs) 
(147) (Fig. 9). In vitro studies have shown that enterovirus infection in cultured islets 
leads to the secretion of a number of ISGs, such as CXCL10, OAS, MDA5 (148-150), 
PKR and MxA (151), however, the chemokine CXCL10 production also seems to vary 
between the islet donors (152).  
 
Figure 9.  Schematic and simplified drawing of type I IFN production upon viral infection. When virus 
enters the cell, it is recognized by pathogen recognition receptors, such as TLRs and MDA5, 
which initiate the signaling cascade leading to activation of IFNα producing genes. Production of 
IFNα leads to the synthesis of ISGs and activates antiviral response in infected and neighboring 
cells.  
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PKR, MxA and other type I IFN-stimulated proteins have also been reported to be 
upregulated in T1D pancreatic islets in vivo, particularly in islets with enterovirus 
VP1 positivity, as well as in enterovirus-infected human beta cell line (133,153-156). 
MxA is a cytoplasmic protein with intrinsic antiviral properties. MxA is considered 
to be an important component of the early innate immune defense in humans (157). 
PKR, however, is constitutively expressed in mammalian cells and has intrinsic 
properties as the first line defense mechanism against infection and as a cell growth 
regulator. PKR phosphorylates eLF-2α as a result of viral infection, which ultimately 
results in general inhibition of translation. This phosphorylation also inhibits viral 
replication. PKR has an ability to exert this antiviral activity on a wide spectrum of 
DNA and RNA viruses (158).  ISGs are also markedly enhanced in insulitic islets of 
living donors with recent-onset T1D (156).  
IFN-α expression has also been associated with hyperexpression of HLA class I 
molecules in human islets (145,159). HLA I pathway has an important role in alerting 
the immune system to virally infected cells. Hyperexpression of class I HLA on islet 
cells has recently been determined to be a defining feature in T1D (160). HLA I 
hyperexpression has been reported in enterovirus-positive, insulin-containing islets 
of T1D subjects but not in non-diabetic controls, regardless of viral presence. Studies 
carried out in isolated human islets and human beta cell lines show that proteins 
involved in antigen presentation, such as HLA-C, and proteins involved in the 
transport of antigens, such as TAP1 (Fig. 8 B), which is associated with the HLA class 
I, were strongly increased upon infection with CV-B4 (154,155). TAP1 is also 
significantly increased in ICIs of T1D donors, correlating with increased class I HLA 
expression (161). It has been suggested that type I IFNs may be the key links 
between genetic susceptibility and environmental risk factors in T1D onset and 
progression (78). Furthermore, the frequency of CAR expression, the receptor for 
CV-Bs, has been reported to be increased in pancreatic islets in T1D and 
autoantibody-positive (AAb+) subjects compared to non-diabetic subjects 
(162,163). 
2.6.6 Murine and cell models 
Murine models have been used widely to analyze various aspects of T1D, including 
the possible connection to enteroviruses. The NOD mice are one of the most used 
mouse strains in T1D studies. These mice spontaneously develop autoimmune T1D, 
starting around 12 weeks after birth. As a model for a human disease, mouse is not 
optimal. For example, one of the major differences between human and NOD 
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mouse pancreas  is the site of virus replication; enteroviruses do not strongly infect 
the pancreatic islets in mice but replicate in the exocrine part of the pancreas, 
whereas many enteroviruses have a tropism to the beta cells in humans 
(129,164,165). Another mouse model, the family of suppressors of cytokine-
signaling (SOCS) transgenic mouse, lacks the interferon response in beta cells, due 
to SOCS-1 and, thus, develops a robust infection in the islets and beta cells upon 
viral infection. This infection is followed by hyperglycemia and loss of beta cells 
(166). Whereas some murine studies have suggested that enterovirus infections are 
linked to the development of T1D by accelerating the onset of the disease (167), 
other studies suggest that enteroviruses may have a contrary impact - protection 
from the disease (168). Studies have revealed, for example, that the virus protects 
the mice from developing autoimmune T1D if a CV-B is introduced into NOD mice 
at young age. (168,169). However, the NOD mice rapidly develop T1D if the 
enterovirus is introduced to NOD mice at an older age (169). The effect of the virus 
in the onset of T1D seems to depend on timing of the infection, virus strain and 
dose. Encephalomyocarditis (EMC) virus is a murine enterovirus that has also been 
used in T1D studies. The mechanism is dependent on the dose of the virus; higher 
titers lead to rapid development of T1D, due to the direct impact of cell destruction 
by viral replication, whereas lower titers cause the recruitment of macrophages, 
which in turn produce soluble mediators that eventually destroy the beta cells (167). 
Isolated human islets have also been used to analyze enterovirus tropism and islet 
response to enterovirus infection. Enteroviruses have been reported to cause both 
lytic and persistent infections in such islets (170-174). They have also been shown 
to affect the insulin production and the organelles involved in insulin secretion but 
not the glucagon production (152,175). The islet cell models support the idea that 
different enterovirus types and strains have different capacity to induce immune 
response in the islets and to destroy beta cells. However, most of the studies have 
been carried out using species B enteroviruses, and it is not known whether these 
viruses differ from other enterovirus species for their ability to damage pancreatic 
islets in vitro. 
Human beta cell lines have recently become available. One of the most widely used 
is the EndoC-βH1 cell line, an immortalized clonal human beta cell line that 
expresses monotypic, insulin-producing beta cells without paracrine effects of other 
cell types during infection. In a recent study by Nyalwidhe et al. (155) CV-B4 was 
used to infect EndoC-βH1 cells in parallel with human islet preparations, and viral-
modified proteins were analyzed 48h post infection by quantitative MS. It was 
shown that infection with CV-B4 induced a reduction in insulin, increased proteins 
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related to antigen-presentation, and that IFN-signaling was the most increased 
canonical pathway identified. 
Persistent or chronic enterovirus infection models have been established in 
pancreatic cell lines. Sane et al. established pancreatic ductal cell line (PANC-1), 
which was infected with a strain of CV-B4 (176). The virus was able to persist in the 
cell line, causing alterations such as the impairment of Pdx1, which is a transcription 
factor required for the formation of endocrine pancreas (176). The virus replicates 
in proportion of cultured cells without overwhelming cytopathic effect (so-called 
carrier state persistence). One of the suggested hypotheses is that enteroviruses 
cause a persistent infection in pancreatic islets in T1D, causing alterations on the 
host cell and possibly mounting the IFN response over time, ultimately by the help 
of acute infection episodes leading to the onset of disease (177-179). 
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3 AIMS OF THE STUDY 
The principal aim of this study was to assess different methods for the detection of 
enteroviruses in cell and tissue samples, and to use these methods to investigate if 
enteroviruses can be detected in pancreas and other tissues of type 1 diabetic 
subjects. The specific objectives of this thesis were the following: 
 
1. To develop a type- and group-targeted method for the detection of 
enteroviruses in formalin-fixed, paraffin-embedded (FFPE) tissue samples 
using QuantiGene ViewRNA in situ hybridization technology (I) 
 
2. To compare the relative sensitivities of RT-PCR, immunohistochemistry, in 
situ hybridization and proteomics for the detection of enteroviruses in 
infected FFPE cell culture samples (II) 
 
3. To study the presence of enteroviruses in pancreas, duodenum, spleen and 
pancreatic lymph node samples obtained from type 1 diabetic, prediabetic 
and non-diabetic subjects (III) by using immunohistochemistry and RT-qPCR  
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4 MATERIALS AND METHODS 
4.1 Viruses and cell lines (I, II) 
Enteroviruses used in studies I and II included 21 enterovirus types, 30 CV-B1 strains 
and 9 CV-B3 strains. The cell lines used in I and II were green monkey kidney cells 
(GMK and Vero), human cervix carcinoma epithelial cells (HeLa), human lung 
carcinoma alveolar basal epithelial cells (A549) and human rhabdomyosarcoma cells 
(RD). 
 
Figure 10.  Schematic presentation of preparing limited dilution series: 1. A549 cells were grown in 
monolayers in T175 flasks and infected with high MOI (multiplicity of infection) of CV-B1. 2. 
Infections were stopped at four different time points and cells from different time points were pooled 
together to obtain viruses in different phases of the replication cycle. 3. The pool of infected cells 
were combined with non-infected A549 cells to produce a dilution series ranging from undiluted 
sample to dilution 10-8 (4.) 
 
In I, cell lines were grown in a monolayer in complete media with 5% FBS and 
subsequently infected with selected viruses in their individual T75 flasks, until 50% 
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cytopathic effect was reached. Cells were harvested by scraping and fixed in 4% 
formaldehyde in PBS for 24-72h prior to dehydration and paraffin embedding. 
In order to establish a dilution series of enterovirus-infected cells, in II, A549 cells 
were grown in monolayers in Nutrient Mixture F-12 Ham, N 6658 (Sigma-Aldrich®) 
medium in T175 bottles and infected with CV-B1 (an ATCC strain) and cell samples 
were collected by scraping 1 h, 2 h, 4 h, and 6 h post infection. The cells from 
different time points of infection were pooled after mechanical detachment, 
washed with the growth medium and immediately combined with uninfected A549 
cells to produce a dilution series ranging from 10-1 to 10-8 (Fig 10).  Each dilution 
aliquot was further divided into ten sub-aliquots and fixed or frozen according to 
the method applied.  
4.2 Cell microarrays (I, II) 
Four different cell microarrays (CMAs) were produced from paraffin blocks, which 
had been infected with different enteroviruses, and used in IHC and ISH. Briefly, 
cylindrical punches (diameter 1 mm) were drilled from individual paraffin-
embedded sample blocks and inserted into new CMA recipient paraffin blocks 
using TMA Master (3D Histech Kft, Hungary). Four different CMAs, named EV 
CMA, CVB1 CMA, CVB3 CMA and Limited dilution series (Table 2, Fig. 11), were 
created (I and II).  5 μm-thick sections were cut from the recipient blocks and 
placed onto microscopic slides for histological staining. 
 
Table 2.  Overview of the CMAs created for probe set and antibody testings (I,II). 
 
CMA Viruses Cell line* 
EV CMA 21 enterovirus types, Adeno C, 
HPeV1 
A549, Vero, HeLa, RD, GMK 
CVB1 CMA 31 CV-B1 strains, echovirus 3 A549 
CVB3 CMA 9 CV-B3 strains, echovirus 3 A549 
Limited dilution series CV-B1 ATCC strain A549 
*A549: human alveolar basal epithelial cell line; Vero and GMK: green monkey kidney cell 
lines; HeLa: human cervix carcinoma epithelial cell line; RD: human rhabdomyosarcoma cell 
line. HPeV1: human parechovirus 1 
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Figure 11.  Schematical presentation of the different FFPE CMAs created for the probe set and antibody 
testings. A) EV CMA, which includes 21 enterovirus types and two non-enteroviruses on six 
different cell lines; B) CVB1 CMA includes 31 different wildtype CV-B1 strains and echovirus 3 on 
A549 cells; C) CVB3 CMA has 10 different wildtype CV-B3 strains and echovirus 3 on A549 cells; 
D) Limited dilution series, which includes a prototype CV-B1 infected undiluted sample, eight 
dilutions of it and a non-infected control sample; E) represents the color codings of different cell 
lines used for the CMAs. Wildtype and prototype status of the viruses used in EV CMA are detailed 
in I, Supplementary Table 2. 
4.3 Murine samples (I) 
NOD and C57BL/6J Rag-/- (B6 Rag-/-) mice used in the study were bred and housed 
in specific pathogen-free animal facilities at Karolinska Institutet, Stockholm, 
Sweden (in collaboration with professor Malin Flodström-Tullberg). Mice were 
infected intra-peritoneally (i.p.) with different types and doses of CV-Bs diluted in 
A 
B 
C 
D E 
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200 μl RPMI medium. Organs were harvested between 3 and 7 days post infection, 
and fixed in 4% formaldehyde in PBS for 24 h prior to dehydration and paraffin 
embedding. For histology, 5 μm thick sections were cut on microscopic slides. 
4.4 Human tissue samples (III) 
Human tissue samples were obtained from nPOD (network for Pancreatic Organ 
Donors with Diabetes) project (https://www.jdrfnpod.org) –funded by JDRF 
(Juvenile Diabetes Research Foundation). The JDRF nPOD program recovers 
transplantation-quality pancreas and other organ samples from T1D donors, non-
diabetic donors with and without islet autoantibodies and from donors with T2D or 
other conditions throughout the USA. The JDRF nPOD distributes these organs to 
investigators in the T1D field, who aim at obtaining information about the 
pathophysiological process of beta cell destruction, the etiology of the disease and 
in the end, who are seeking methods for disease prevention and reversal strategies 
(180).  
Pancreas, duodenum, spleen and pancreatic lymph node (PLN) samples from T1D, 
T1D-related autoantibody-positive (AAb+) and non-diabetic organ donors were 
obtained from the JDRF nPOD collection. FFPE samples were used for 
immunohistochemical studies and frozen unfixed samples for RT-qPCR analyses. 
Tables 3 and 4 summarize the numbers and details of the sample types used.  
 
Table 3.  Number of nPOD organ donors and FFPE samples analyzed by immunohistochemistry in 
III. 
 
Tissue T1D  
N=64 
AAb+ 
 N=19 
Control 
 N=49 
Total N of different donors 
per tissue  
N total = 132 
Pancreas 64 19 49 132  
Spleen 50 17 38 105  
Duodenum 38 14 22 74  
PLN 9 1 0 10 
Total N of 
samples 
152 50 109 311 
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Table 4.  Number of  nPOD donors and samples analysed by RT-qPCR in III. 
 
Tissue T1D  
N=41 
AAb+ 
 N=17 
Control 
 N=32 
Total N of different donors 
per tissue  
N total = 90 
Pancreas 33 16 29 78  
Spleen 38 15 27 80  
Duodenum 30 13 21 64  
PLN 5 3 0 8 
Total N of 
samples 
106 47 77 230 
 
Selected cases from T1D, AAb+ and control donors with insulin and enterovirus VP1-
positive pancreatic islets were further analyzed for specific markers (see 4.6, Tables 
7 and 8) to obtain information about differences between donor groups. These 
groups included 12 T1D cases, 7 AAb+ cases and 12 non-diabetic controls.  
4.5 In situ hybridization (I, II) 
4.5.1 Probe set design (I) 
Custom probe sets for enteroviruses were designed for the QuantiGene® ViewRNA 
Tissue Assay (Affymetrix, Santa Clara, California, USA). Two different probe sets 
were designed to detect an individual enterovirus type, CV-B1 (named: CVB1 and 
CVB1Sub) and two for species-specific detection (named: EV AB and EV B) targeting 
mainly EV species A and B and EV B, respectively. The design was based either on a 
sequence of one viral strain (probes CVB1Sub and EV B) or on a consensus sequence 
of multiple viruses (probes CVB1 and EV AB). Sequences were aligned using the 
Clustal X program. The consensus sequence was extracted and used as a template 
for probe design. The probe templates were sent to Affymetrix’s probe specialist, 
who prepared these custom probe sets. 
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4.5.2 Optimization of tissue pretreatment conditions 
In the QuantiGene® system, the sample goes through specific pretreatment steps 
prior to the target probe hybridization. After removal of paraffin and alcohol 
dehydrations steps, the tissue is pretreated by boiling in a pretreatment solution at 
95°C, followed by an incubation in a protease solution at 40°C. The boiling and 
protease incubation times are tissue dependent. Table 5 details the optimal times 
for human and mouse tissue samples and cell samples for QuantiGene® ViewRNA.  
 
Table 5.  Optimized pretreatment times (min) for boiling and protease treatment per sample type. 
Optimal times were also selected for multi-tissue slides, i.e.. slides containing mouse pancreas, 
spleen, heart and liver tissues. Some tissues were not optimized individually, and, therefore 
guidelines from the manufacturer are marked in the table. 
 
Species 
or 
Sample 
Tissue Boiling 
time (min) 
Protease 
incubation 
time (min) 
Boiling and protease 
times (min) for multi-
tissue slides 
Human Pancreas 10 10 not tested 
 Duodenum 5 17 not tested 
Mouse  Pancreas 5 10 10,15 
 Spleen - - 10,15 
 Heart 10* 40* 10,15 
 Liver 20* 20* 10,15 
Cells -  5 10 - 
*Guideline times suggested by the manufacturer 
4.5.3 Workflow 
ISH was performed both in Tampere virus laboratory and in a collaborative 
laboratory in Gainesville, Florida, US, using different commercially available 
methods. Sections from FFPE samples were used in both Tampere (I, II) and 
Gainesville (II). In Tampere, the QuantiGene® ViewRNA Tissue Assay (Affymetrix) 
was applied with different enterovirus-specific probe sets according to the 
manufacturer’s instructions. Target-specific hybridization was followed by signal 
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amplification using specific oligonucleotides conjugated to alkaline phosphatase. 
Fast Red substrate was used for detection under both brightfield and fluorescent 
lights. In Gainesville, ISH was performed using the RNAscope 2.0 High Definition 
Assay (Advanced Cell Diagnostics, Hayward, California, USA) according to the 
manufacturer’s instructions. Two probes that were specific for the whole CV-B 
group and CV-B3 only, were tested. Deparaffinized sections were hybridized to 
probes followed by amplification by serial application of amplifiers and peroxidase 
labels. Hybridization was visualized by DAB and brightfield light microscopy. 
4.6 Immunohistochemistry (II, III) 
Samples from FFPE limited dilution series (Fig.11 D) were immunostained in three 
different laboratories, Tampere, Exeter and Uppsala, using methods that were 
individually optimized in these laboratories. Primary analyses were done using a 
commercially available antibody (clone 5D8/1, Dako) raised against enterovirus VP1 
protein. The clone 5D8/1 staining methods were previously validated between three 
laboratories. In addition to clone 5D8/1, polyclonal antibodies produced in rabbits 
against each of the viral capsid proteins VP1, VP2, VP3 and VP4 of CV-B4 Tuscany 
strain (GenBank database – accession no. DQ480420) were analyzed in the Tampere 
and Exeter laboratories, and staining was performed similarly to clone 5D8/1. Table 
6 details the concentrations of the CV-B4 VP1-VP4 antibodies used in these 
laboratories. Antibody specificities to different enterovirus types was also tested 
using the CMAs (see Fig. 11) and the selected human tissue samples, which had been 
previously found positive for clone 5D8/1 VP1.  
 
Table 6.  Concentrations of the rabbit CV-B4 VP1-VP4 antibodies used in the IHC studies in Tampere 
and Exeter (II). 
 
Laboratory VP1A VP1B VP2B VP3A VP3B VP4B 
Tampere (FIN) 1:3000 1:4000 1:3200 1:1500 1:5000 1:2500 
Exeter (UK) 1:3000 1:6000 1:3000 1:2500 1:9000 1:2000 
 
Enterovirus VP1 stainings for human pancreas, spleen, duodenum and PLN were 
performed using clone 5D8/1 (III). Part of the spleen samples were also stained in 
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Exeter laboratory to evaluate concordance in the spleen VP1 results. Half of the 
pancreas sections were also stained with insulin in Tampere and half in Exeter. In 
the Tampere lab, the automated Ventana BenchMark LT (Ventana Medical Systems, 
Inc.) and the ultraView™ Universal detection system was used for the chromogenic 
stainings. In Exeter, the stainings were performed manually as previously reported 
(133). Table 7 summarizes the antibodies and staining conditions of chromogenic 
IHC. 
 
Table 7.  Antibody conditions used in the chromogenic stainings. 
 
1̊Ab Ab details HIER Dilution Incubation 2̊ Ab Type of 
protocol 
Study 
VP1 
Tampere 
Clone 
5D8/1 Dako 
Tris-EDTA 
pH8.5 
1/300 
 
30 min, 37̊C 
 
UltraView 
HRP  
Automated 
 
(II, III) 
VP1 
Exeter 
Clone 
5D8/1 Dako 
Citrate pH6 1/1400 1h, RT Envision 
HRP  
Manual (II, III) 
VP1 
Uppsala 
Clone 
5D8/1 Dako 
not 
available 
1/2000 not 
available 
Link 38 
Dako 
Automated (II) 
CV-B4 VP1-
VP4 
Tampere 
In-house Tris-EDTA 
pH8.5 
Table 6. 30 min, 37̊C 
 
UltraView 
HRP  
Automated 
 
(II) 
CV-B4 VP1-
VP4 
Exeter 
In-house Citrate pH6 Table 6. 1h, RT Envision 
HRP  
Manual (II) 
Insulin 
Tampere 
Thermo Tris-EDTA 
pH8.5 
1/2000 
 
30 min, 37̊C 
 
UltraView 
HRP  
Automated 
 
(III) 
Insulin/ 
glucagon 
Exeter 
Dako/  
Abcam 
Citrate pH6 1/700; 
1/2000 
1h RT each HRP / AP Manual (III) 
HLA Class I Abcam Citrate pH6 1/1500 45 min, RT Envision 
HRP 
Manual  
PKR Abcam Citrate pH6 1/700 O/N, +4C Envision 
HRP 
Manual  
Ab, antibody; HIER, heat-induced epitope retrieval; HRP, horseradish peroxidase; AP, 
alkaline phosphatase; RT, room temperature 
                 47 
IHC and IF double- and triple-stainings in the Exeter laboratory were performed 
together with Dr. Sarah Richardson (P.I. Noel Morgan) to study specific markers of 
inflammation in the pancreas of selected nPOD organ donors. Pancreas samples 
were stained using the following primary antibodies: enterovirus VP1 (clone 5D8/1), 
insulin, glucagon, PKR, and MxA. Briefly, after removal of the paraffin, the samples 
were dehydrated and rehydrated, followed by a heat-induced, epitope-retrieval 
(HIER) step. The primary antibody was incubated either 1h at RT or overnight (O/N) 
at 4°C, depending on the antibody. Slides were washed, followed by a corresponding 
secondary antibody (Alexa Fluor 488/568/633, Thermo Fisher Scientific) incubation. 
After wash steps, the slides were mounted and visualized using fluorescence 
microscope. Table 8 summarizes the details of the antibodies and staining 
conditions. 
 
Table 8.  Antibody conditions used in the IF stainings. 
 
1 ̊Ab Ab details HIER Dilution Incubation 
VP1 
 
Clone 5D8/1, Dako Citrate pH6 1/1400 O/N at +4C 
Insulin Dako Citrate pH6 1/700 1h at RT 
Glucagon Abcam Citrate pH6 1/5000 1h at RT 
PKR Abcam Citrate pH6 1/700 O/N at +4C 
MxA from O. Haller Citrate pH6 1/500 1h at RT 
Ab, antibody; HIER, heat-induced epitope retrieval; O/N, overnight; RT, room temperature 
4.7 RT-qPCR (II, III) 
Frozen, unfixed cell samples (II) or human organ donor samples (III) were analyzed 
by RT-PCR. RT-PCR analyses were performed in two different laboratories: Tampere, 
Finland (II, III) and Uppsala, Sweden (II). 
 48 
In Tampere laboratory, RNA was extracted from 140 μl of cell sample using the Viral 
RNA Kit (Qiagen, Hilden, Germany). Real-time RT-qPCR, detecting the 5’UTR from 
enteroviral RNA, was performed as previously described (21) and briefly described 
here. The real-time PCR run was performed using the Quantitect Probe kit (Qiagen, 
Hilden, Germany) using Taqman chemistry.  RT-qPCR mix was combined with 
QuantiTect Probe PCR Master Mix *1, forward primer 0,9 μM, reverse primer 4- 0,9 
μM, probe I 0,3 μM, probe II 0,3μM, QuantiTect RT Mix 0,5 μl, Template RNA 2μl, 
RNase-free water up to 10μl. The primers and probes used in the method were: 
forward primer; CGG CCC CTG AAT GCG GCT AA, reverse primer; GAA ACA CGG ACA 
CCC AAA GTA, probe 1; FAM-TCT GTG GCG GAA CCG ACT A-TAMRA and probe 2; 
FAM-TCT GCA GCG GAA CCG ACT A-TAMRA. The cycler conditions were: 50oC 30min, 
95oC 15min following by 2-step cycling up to 50 cycles 94oC 15s and 60oC 60s. In 
Uppsala, viral RNA was extracted from 100 μl of cell samples using RNeasy Mini kit 
(Qiagen). 50 ng of total RNA per sample were primed with virus-specific primers and 
reverse transcribed to cDNA with SuperScriptIITM RT (Invitrogen) according to the 
manufacturer’s instructions. A semi-nested enterovirus PCR was performed in the 
conserved 5´region of the genome using following primers: forward primer; 
GCCCCTGAATGCGGCTAAT 100 (pmol/μl) Rev GATGGCCAATCCAATAGCT (100 
pmol/μl) and reverse primer; ATTGTCACCATAAGCAGCCA (100 pmol/μl). Mini elute 
gel extraction kit (Qiagen, Sweden) was used to purify the positive PCR products that 
were excised from the gel (130). 
In paper III, frozen human tissue samples from the nPOD collection contained 
pancreas, duodenum, spleen and pancreatic lymph nodes (PLNs) from T1D, AAb+ 
and control donors. Samples were either snap frozen, OCT tissue slabs (~50 μm 
slides cut from optimal cutting temperature (OCT) embedded tissue) or stored in 
RNALater. The tissue was homogenized with PowerLyzer® 24 Bench Top Bead-Based 
Homogenizer (MO BIO Laboratories, USA), and the RNA was extracted with RNeasy® 
Plus Universal kit. As in paper II, the presence of enterovirus RNA was analyzed after 
RNA extraction with real-time RT-qPCR. 
4.8 Proteomics (II) 
The use of proteomics technologies is a novel approach in the enterovirus detection 
field. The liquid chromatographic (LC) and mass spectrometry (MS) analyses in 
paper II were performed by a collaborative laboratory in Eastern Virginia Medical 
School, Virginia, USA. LC/MRM/MS/MS was targeted to recognize viral peptides 
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from the CV-B1-infected dilution series cell extracts. Briefly, the frozen and unfixed 
dilution series samples were lysed with sonication and solubilized. Aliquots of the 
protein samples were reduced and alkylated, after which proteins were digested 
with trypsin to generate peptides. The peptides were purified and concentrated to 
dryness prior to LC/MRM/MS/MS. The tryptic peptides were analyzed in a mass 
spectrometer, and FASTA-formatted virus protein sequences were uploaded into 
Skyline software to predict signature peptides for CV-B1 peptides. A CV-B1 2C 
protein peptide with sequence SVATNLIGR was selected for subsequent analysis and 
quantification based on the high intensities of both the precursor ion (Q1 m/z) and 
fragment ions (Q3 m/z) and the lack of signals in the non-infected A549 cells. The 
tryptic peptide samples corresponding to 16 μg of sample were automatically 
injected onto the column, separated and analyzed by LC/MRM/MS/MS. Relative 
intensity-based quantitation was achieved by comparing the area under the curve 
for the peptide transition pairs in the extracted ion chromatograms (XIC) for each 
dilution step. 
4.9 Microscopy (I-III) 
Most of the stained slides, with the exception of the fluorescent-labeled slides, were 
analyzed using scanned slide images. The scanning was done with an automated 
Objective Imaging Surveyor virtual slide scanner (SlideStrider, Jilab, Finland), where 
the Digitization was performed at a resolution of 0.4 microns per pixel (using 20X 
PlanApochromatic microscope objective). Image data was converted to JPEG2000 
format (181) and the JVSView program (http://jvsmicroscope.uta.fi/?q=jvsview) 
was used to open the images. The Olympus BX60 wide-field brightfield/fluorescence 
microscope (Olympus America, Melville, NY, USA) was used to verify the results in I-
III. The fluorescent-labeled slides were analyzed using Nikon 50i Microscope (Nikon 
Corporation, Japan) in IF pancreas studies. 
4.10 Statistical methods (III) 
The statistical analyses for paper III were performed using the SPSS 22.0 program 
(IBM Corp., USA) for Windows. Frequency comparison was performed with the 
Pearson’s Χ2 and Fisher’s exact tests. 
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5 RESULTS 
5.1 In situ hybridization probe design for specific detection of 
enterovirus types (I) 
There is a need for enterovirus type-specific detection methods that could be used 
in  histological studies. Therefore, specific RNA -probes for selected enteroviruses 
were designed and used in QuantiGene® ViewRNA ISH technique. The EV AB probe 
recognized all tested viruses from enterovirus species A and B. The recognition 
spectrum of EV B probe was similar to that of EV AB probe, with the exception of 
poliovirus 3 (PV3) -vaccine strain, which belongs to Enterovirus C. EV B probe didn’t 
recognize PV3, while EV AB did (I, Table 2). Nevertheless, the overall intensity of the 
staining of different virus types was stronger with the EV AB probe. Figure 12 
elaborates the differences between the EV AB and EV B probe sets.  
The CVB1 probe stained all but one CV-B1 strain strongly, with clear and abundant 
signal, but it also reacted weakly with some other CV-B types. The CVB1Sub probe 
gave a more narrow recognition spectrum among the tested CV-B1 strains and did 
not react with any other virus type (Fig. 13). Every probe gave a negative result in 
the mock-infected cells as well as in the human parechovirus-1 (HPeV-1) and 
adenovirus C infected cells (I, Table 2.). The probes were also tested in CV-B1, CV-
B3, CV-B4, CV-B5 and CV-B 6 -infected mouse pancreata (I, Table 4, Fig. 2). The 
results were consistent with the results obtained using infected cells (Table 9). 
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Figure 12.  Example images showing the alignment results of the designed probes. A) EV AB and B) 
EV B probe sets. Sequences of different enterovirus strains are shown in colors. The red line marks 
the estimated 80-85% coverage (here 82%) that the probe set requires to recognize its target. This 
figure shows that EV AB has a much greater coverage of different enterovirus strains compared to 
EV B, since more EV AB sequences are above the threshold line compared to EV B. Y-axis shows 
the similarity and X-axis the nucleotide position on the probe set. 
 
 
A 
B 
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Figure 13.  Specificity of CVB1Sub probe on GMK cells infected with different enterovirus types. The 
probe recognized only CV-B1 (positive signal indicated in red color) and none of the other 
enterovirus types tested. GMK control and HPeV-1 were also negative. 
 
Table 9.  Enterovirus positivity of the probe set in different CMAs and infected mice. The two widely 
recognizing probes, EV AB and EV B, detected (almost) all tested enterovirus types from 
Enterovirus A, B and C while type-targeted probes had a more narrow recognition spectrum. 
 
Sample Enterovirus 
species 
Detected enterovirus types (n/n) 
  EV AB EV B CVB1 CVB1Sub 
EV CMA A, B and C 20/21 19/21 4/21 1/21 
CVB1 CMA B 31/31 27/31 30/31 14/31 
CV-B -infected mice B 5/5 5/5 3/5 1/5 
 
5.2 Co-staining for enterovirus and insulin in human and mice 
pancreas using in situ hybridization 
In order to see whether enterovirus RNA can be located to insulin-producing beta 
cells of the human pancreas, a method for co-staining insulin and enterovirus, was 
developed with the ISH (QuantiGene® ViewRNA, Affymetrix) system. Infected 
mouse pancreas and human pancreas with IHC-confirmed enterovirus VP1 positivity 
was used for the purpose. The co-staining worked well in infected mouse pancreas, 
                 53 
where insulin and enterovirus were not expected to colocalize, giving clear signals 
from both targets, insulin within the islets and enteroviruses within the exocrine 
pancreas (Fig. 14 C and D).  
 
Figure 14.  Co-immunstaining of insulin and enterovirus in human and mouse pancreas. ISH staining 
of insulin (blue; A, B, C) and enterovirus (red; D, E, F) in human (A, B, D, E) and mouse (C, F) 
pancreas. Co-localization of the two targets in human pancreatic islets turned the signal into purple 
(A and B, purple arrows and color). In E fluorescence image of the stained islet shows strong 
enterovirus signal. No viral signal is observed in the region where only blue insulin color is seen on 
the brightfield image (arrows in B and E). In D, single staining of enterovirus probe shows no signal 
within the same islets (encircled) of the adjacent slide of A. In C, clear enterovirus signal was seen 
in the exocrine tissue of mouse pancreas. A small islet is also stained with insulin in the middle. F 
shows insulin staining in non-infected mouse pancreas. 
 
Instead, different results were obtained using human pancreas, where the two 
targets are expected to co-localize. Co-localization of the two targets was observed 
in some of the islets. Co-localization showed in purple in brightfield visualization, as 
the two signals, red for virus and blue for insulin, merged (Fig 14 A and B). When 
looking at the channel with a viral signal only, it completely matched the purple 
pattern seen in brightfield of these islets. An adjacent pancreatic section was stained 
with enterovirus probe only to confirm the results, but no viral signal was observed 
in any of the islets. This was regardless of the fact that signal was observed in the 
adjacent slide in co-staining of enterovirus and insulin (Fig. 14 A and D). In addition, 
these particular islets were also confirmed enterovirus VP1-positive by IHC in the 
adjacent section. None of the tested human pancreatic sections were positive for 
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enterovirus RNA when only the viral probe was used. Signal was seen co-localizing 
with insulin in some islets in co-stainings with insulin. As enterovirus-positive signal 
in human pancreas was seen only in co-staining with insulin but not with enterovirus 
probe only, it was decided that the results were inconclusive. Therefore, the 
enterovirus ISH technique was not used for staining the human pancreas tissue in 
III.  
The enterovirus (EV B) probe set was also used alone to locate the viral RNA in a set 
of human pancreas samples from the nPOD collection. No clear positive signal was 
found in any of the pancreas samples (data not shown), consistent with the results 
presented in Fig. 14 D. 
5.3 Relative sensitivity of different enterovirus detection methods (II) 
To test the relative sensitivity of different enterovirus detection methods, A549 cells 
were infected with CV-B1 and diluted with non-infected A549 cells in a serial manner 
ranging from undiluted infected cell suspension to a dilution 10-8. All methods tested 
were able to detect CV-B1 in infected A549 cells but gave no signal in uninfected 
cells. However, depending on the method used, the detection limit varied across a 
range from 10-4 to 10-8 (dilution factor of infected to uninfected cells). RT-qPCR was 
the most sensitive method and was capable of detecting the most diluted virus 
sample in one of the test laboratories. The second laboratory achieved almost the 
same sensitivity using a different RT-PCR method. LC/MRM/MS/MS demonstrated 
high sensitivity and was also able to specifically identify virus peptides in extracts of 
infected A549 cells. IHC reached detection limit of dilutions between 10-3 and 10-6, 
depending on the laboratory and antibody used. The most sensitive IHC method was 
based on the commercial antibody clone 5D8/1 (Dako). Both of the ISH methods 
performed equally well, reaching dilution 10-4, regardless of the probe used. Table 
10 summarizes the sensitivities of the different methods. 
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Table 10.  Comparison of the sensitivity of different methodologies to detect CV-B1 in A549 cells. 
(Modified from II, Table 1) 
 
Method Highest dilution reached Target 
RT-qPCR (frozen cells) 
 
 
          semi-nested (Uppsala) 10-8 5’UTR 
          real-time (Tampere) 10-7 5’UTR 
Proteomics (frozen cells) 
 
 
          LC/MRM/MS/MS 10-7  
          MRM 10-7  
IHC (FFPE cells) 
 
 
          anti-EV VP1 Clone 5D8/1 10-6 VP1 capsid protein 
          anti-CVB4 VP antibodies 10-4 VP1, VP2, VP3 and 
VP4 capsid proteins of 
CVB4 
ISH (FFPE cells)  
          QuantiGene ViewRNA (Affymetrix) 10-4 Conserved regions from 
genomic P1 region 
          RNAscope (ACD) 10-4 consecutive regions 
from CVB3 VP3-VP1 
5.4 Comparison of the recognition spectrum of enterovirus probes and 
antibodies 
5.4.1 EV AB probe and anti-enterovirus VP1 clone 5D8/1 (I) 
The main focus of paper I was to develop novel probe sets with different binding 
properties to selected enterovirus types. It also provided a good opportunity to 
compare the recognition spectrums between the enterovirus VP1 antibody clone 
5D8/1 and the most widely recognizing probe set EV AB (i.e., protein vs. RNA 
detection) using the EV CMA. As a result, both EV AB and clone 5D8/1 recognized 
the same enterovirus types but the intensity of staining varied depending on the 
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enterovirus type (Table 11). The main difference was observed in the recognition of 
viruses from EV A species. Clone 5D8/1 was able to bind to most Enterovirus As only 
weakly, whereas EV AB showed a much stronger reaction towards Enterovirus As, 
with the exception of CV-A5, and was binding well to almost all tested enterovirus 
types. EV AB also overcame clone 5D8/1 in the recognition of selected echoviruses 
by giving a stronger signal by wider distribution in the infected sample. Both were 
also able to recognize PV3, which represents enterovirus species C, and as expected, 
neither one was binding to uninfected cells or to non-enteroviruses, including 
adenovirus C or HPeV-1. Neither EV AB nor 5D8/1 bound to EV71, which was the 
only tested enterovirus type that remained undetected in this study. 
 
Table 11.  Comparison of the ability of EV AB probe set and anti-VP1 clone 5D8/1 to recognize 
different enterovirus types, on a scale from – (negative) to +++ (strong positive). 
Virus Probe set Anti-VP1 antibody 
Species type EV AB Clone 5D8/1 
EV B CV-B1 +++ +++ 
EV B CV-B2 +++ +++ 
EV B CV-B3 +++ +++ 
EV B CV-B4 +++ +++ 
EV B CV-B5 +++ +++ 
EV B CV-B6 +++ ++ 
EV B E-3 +++ + 
EV B E-4 +++ + 
EV B E-6 +++ +++ 
EV B E-9 +++ ++ 
EV B E-11 +++ + 
EV B E-30 +++ +++ 
EV B CV-A9 +++ +++ 
EV A CV-A2 ++ + 
EV A CV-A4 ++ + 
EV A CV-A5 + ++ 
EV A CV-A6 ++ + 
EV A CV-A10 +++ + 
EV A CV-A16 +++ + 
EV A EV-A71 - - 
EV C PV-3 ++ ++ 
Adenovirus VR846 - - 
HPeV HPeV1 - - 
EV, enterovirus; CV, coxsackievirus; E, echovirus; HPeV, human parechovirus 
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5.4.2 Anti-CV-B4 VP1-VP4 antibodies 
Polyclonal antibodies produced in rabbits against the viral capsid proteins VP1, VP2, 
VP3 and VP4 of purified CV-B4 were tested on different CMAs and selected human 
pancreas and duodenum samples that had been stained VP1-positive with the clone 
5D8/1. All polyclonal antibodies recognized viruses from enterovirus species B, 
although a slight variation between the antibodies could be observed (II, Fig. 3). All 
viruses from enterovirus species A, and the non-enteroviruses were negative with 
these VP1-VP3 antibodies; however, VP4B antibody was able to recognize CV-A4 
and CV-A6 weakly. In contrast, the clone 5D8/1 bound to all tested enterovirus A 
types weakly. Minor unspecific staining was observed in GMK control cell with every 
rabbit VP1-VP4 antibodies and to RD control cells with clone 5D8/1. Overall, among 
the tested rabbit antibodies, antibodies against VP3 capsid protein gave the best 
performance in terms of recognition spectrum and signal strength. According to the 
limited dilution series, however, the sensitivity of these CV-B4 VP1-VP4 antibodies 
did not reach the sensitivity of clone 5D8/1. Also, staining an adjacent slide from a 
strongly VP1 (clone 5D8/1) positive human duodenum and pancreas, did not 
provide any positivity with VP3B, also suggesting a lesser sensitivity compared to 
the clone 5D8/1. 
5.5 Analyses of tissue samples of type 1 diabetic patients (III) 
5.5.1 Insulin and glucagon in FFPE tissue samples (III) 
In paper III, the insulin status of the adjacent section to the slide stained with anti-
enterovirus VP1 antibody was analyzed from 132 donors (64 T1D, 19 AAb+, 49 non-
diabetic controls). All non-diabetic and AAb+ donors were positive for insulin in IHC, 
whereas only 42% (N=27) of T1D donors showed insulin-containing islets or residual 
insulin-positive cells in the pancreas. Insulin positivity with respect to T1D duration 
showed a decreasing trend with longer disease duration (p=0.011; Fig. 15).  
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Figure 15.  Insulin positivity decreased with increasing T1D duration. With T1D duration 0-10 
years, 60% of donors still had residual insulin-positive cells, whereas with more than 21 years 
duration only 13% (N=2) had insulin-positive cells. 
 
Markers of inflammation and insulin status were analyzed in selected nPOD 
pancreases from T1D, AAb+ and control donor groups (see results of inflammation 
markers in 5.5.6). Insulin-containing islets were detected by IHC in every donor 
analyzed from those samples; however, T1D donors also had insulin-deficient islets 
to a varying extent. The insulin was also used together with glucagon to form maps 
of the stained pancreas slides making it possible to localize other markers within or 
around specific islets. Fig. 16 shows an example of this. 
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Figure 16.  Images of adjacent pancreatic slides stained with insulin and glucagon. A) Insulin (brown) 
and glucagon (red) in an AAb+ donor. B) Rectangular area in A magnified. C) Class I HLA of the 
same islets in adjacent section These images represent normal expression levels of the markers.  
5.5.2 Enterovirus protein in FFPE tissue samples (III) 
FFPE tissue samples from altogether 132 organ donors were analyzed for the 
presence of enterovirus VP1 protein using clone 5D8/1. The VP1 positivity was found 
in the pancreas within the islets but occasionally also in the exocrine pancreas. 
Based on morphology, these were suspected to be ductal cells. However, no staining 
with specific ductal cell markers was performed. The number of VP1-positive cells 
per islet varied from one cell to over 20 cells and from one to hundreds of positive 
cells per pancreatic section. One positive cell within an islet in the entire section was 
considered enough to call the sample enterovirus-positive. Only islet positivity was 
counted as positive. T1D patients were most frequently enterovirus positive (70 %) 
A 
B C
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among the insulin-positive donors, followed by AAb+ and non-diabetic donors (53 
% and 33 %, respectively, p=0.006; Table 12). Similarly to the pancreas, one or more 
enterovirus-positive cells in the duodenum or spleen within the entire section was 
counted as positive. Enterovirus VP1 in the duodenal tissue was more frequently 
found in T1D and AAb+ donors compared to control donors (Table 12, p=0.078). The 
number of VP1-positive cells varied from one positive cell to dozens per section, 
regardless of the donor group, and the positivity was located mostly to Brunner’s 
glands. T1D donors tended to be more frequently VP1-positive in the spleen than 
AAb+ and control donors but without statistical significance (Table 12, p=0.375). The 
positivity usually varied from one VP1-positive cell to ten positive cells per section, 
and most of the positive cells were located in the spleen’s follicular regions. PLNs 
were available only from 10 donors (nine T1D and one AAb+), and six out of ten 
were positive for enterovirus (Table 12). Table 12 shows the details of the VP1 
positivity within each tissue of the different donor groups. Fig 17 shows typical 
images of enterovirus-positive samples. 
 
Table 12.  Enterovirus VP1 positivity in pancreas, spleen, duodenum and PLN of T1D, AAb+ and 
control donors. Table adapted from III. 
 
 Pancreatic islets Spleen Duodenum PLN 
 N % 
positive 
N % 
positive 
N % 
positive 
N % 
positive 
All T1D 64 42 % 50 40 % 38 40 % 9 56 % 
Ins+T1D 27 70 % 23 35 % 16 38 % 4 50 % 
Aab+ 19 53 % 17 29 % 14 40 % 1 100 % 
Control 49 33 % 38 26 % 22 14 % 0  
Total 132  105  74  10  
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Figure 17.  Enterovirus VP1-positivity (brown) in different tissues. A) pancreatic islets B) duodenum C) 
spleen D) PLN. The amount of positive cells can vary from one to dozens (or even hundreds) of 
cells per section. 
5.5.3 Correlation of enterovirus positivity in different organs (III) 
Tissue samples from altogether 132 organ donors were included in the study. All 
donors had a pancreas sample for enterovirus VP1 analysis, and most of them 
(N=107) also had a sample from at least one other organ. When comparing VP1 
positivity in pancreatic islets of donors with residual insulin-containing islets, it was 
observed that 39% of T1D donors and 41% of the AAb+ donors were also 
enterovirus-positive in one or more other organs, compared to only 10% of the 
control donors (p=0.010 and p=0.012; Table 5 in III). Individual comparison of 
pancreas to spleen or pancreas to duodenum or PLN showed no association in 
enterovirus positivity; however, a negative correlation was observed in the 
presence of enteroviruses between pancreas and duodenum (p=0.039; data not 
shown). 
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5.5.4 Insulin and enterovirus positivity according to the duration of type 1 
diabetes (III) 
Of the insulin-positive T1D subjects (N=27), 70% were enterovirus VP1-positive in 
the islets. When evaluating the VP1 positivity in relation to T1D duration, an inverse 
correlation was found, since enterovirus positivity decreased with increasing 
disease duration (p=0.034; Fig. 18), reflecting the number of beta cells left within 
the pancreas section.  
 
 
Figure 18.  Enterovirus VP1 positivity decreases with increasing T1D duration. With shorter (0-10 years) 
duration 83% of T1D donors are VP1-positive. The VP1 positivity decreases to 57% with 11-20 
years duration, and none of the donors was VP1-positive after more than 21 years of disease 
duration. 
5.5.5 Enterovirus RNA in frozen tissue samples (III) 
Altogether 231 human tissue samples were analyzed for the presence of enteroviral 
RNA using RT-qPCR. Enterovirus RNA was found in selected samples in all organs 
examined, except in duodenum (Table 13). Approximately half of the T1D donors 
had insulin-containing islets, and all enterovirus RNA-positive samples were found 
from insulin-positive donors. The aliquot type of the sample (snap frozen tissue 
samples, tissue sample stored in RNALater,  or frozen tissue slab) had no effect on 
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the enterovirus positivity, except possibly with duodenum samples, which were 
mostly 50 μm thick tissue slabs. 
 
Table 13.  Enterovirus RNA positivity per tissue and donor type. 
 
Tissue  NEV+ / N TOTAL EV positivity (%) within donor group, (NEV+/ NTOTAL) 
 
T1D AAb+ Control 
Pancreas       15/78 9 % (3/33) 50 % (8/16) 14 % (4/29) 
PLN               2/8 20 % (1/5) 33 % (1/3) No sample 
Spleen           6/80 10 % (4/38) 0 % (0/15) 7 % (2/27) 
Duodenum     0/64 0 % (0/30) 0 % (0/13) 0 % (0/21) 
 
5.5.6 Immune responses during virus infection  
FFPE pancreatic sections from 12 T1D, 7 AAb+ and 12 non-diabetic organ donors 
from the nPOD collection were analyzed for class I HLA, PKR and MxA. All donors 
were positive for enterovirus VP1 in the islets. The aim was to study whether the 
intracellular response to viral infection (measured by upregulation of PKR, in VP1-
positive cells) or the intercellular responses among islet cells (measured as 
upregulation of class I HLA and MxA across the whole islet) differed between T1D 
and controls. Consecutive sections of FFPE pancreas samples were immunostained 
for insulin, glucagon, PKR and class I HLA. Co-immunofluorescence studies were also 
performed in a sequential manner on a subset of cases to assess VP1, PKR, insulin 
and MxA, and their possible co-localization.  
As a result, PKR was selectively upregulated in enterovirus VP1-positive beta cells, 
regardless of the donor status (Fig. 19). A clear reduction of insulin expression was 
observed in the VP1+PKR+ cells in cases where multiple VP1-positive beta cells per 
islet were detected, which is consistent with the host protein translational arrest 
induced by PKR or viral proteases (Fig. 20).  
 64 
 
 
Figure 19.  Class I MHC expression in VP1-positive islet of T1D and non-diabetic donor. A clear 
difference in the class I MHC protein expression was observed between T1D and non-diabetics. 
T1D donors had HLA I hyperexpression in the enterovirus VP1-positive islets (D), whereas normal 
levels of HLA I were observed in enterovirus VP1-positive islets of non-diabetic donors (H). PKR 
expression locates to VP1-positive cells in both donor groups (A, B, E and F)   
 
Results from class I HLA stainings showed a marked difference between non-
diabetic donors and subjects with T1D. Islets with enterovirus VP1 positivity hyper-
expressed class I HLA molecules in T1D and a subset of AAb+ donors, whereas the 
islet class I HLA protein expression was normal, regardless of viral presence (Fig. 19) 
in non-diabetic controls. 
 
 
Figure 20.  Reduction of insulin expression in islets with multiple enterovirus VP1-positive cells. Co-
immunofluorescence staining of an islet with multiple VP1-positive cells. White arrows indicate to 
a VP1-positive beta cell with reduced levels of insulin. Orange arrows indicate to a strongly VP1-
positive presumed beta cell, with no insulin. A) Insulin B) enterovirus VP1 C) glucagon D) merged 
image, nuclei stained with DAPI.  
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MxA protein was specifically upregulated in enterovirus VP1-positive islets of all five 
T1D donors and all four AAb+ donors studied. However, MxA upregulation was not 
observed in the VP1-positive islets of control donors (Fig. 21). The elevated MxA 
production was only seen in beta cells and not in alpha cells, despite the fact that 
both cell types hyperexpressed HLA I (data not shown).  
 
 
Figure 21.  PKR and MxA expression in pancres of T1D and control donors. PKR (red; indicated by 
white arrows) was upregulated selectively in enterovirus VP1-positive islets regardless of donor 
status. By contrast, MxA (green) was seen in many more islets than PKR but it occurred only in 
islets of T1D donors (lower panels) and not in controls (upper panels). Insulin is marked with blue 
in the figure. 
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6 DISCUSSION 
Enterovirus infections have been linked to T1D in several epidemiological studies 
but the actual mechanism leading to beta cell damage and cessation of insulin 
production remains unknown. It would therefore be important to study the nature 
of enterovirus and T1D association further. Studies addressing the tropism of 
enteroviruses to beta cells and possible persistence of enteroviruses in the 
pancreatic cells would help to understand the mechanisms of this association. In 
addition, development of sensitive methods for the detection of enteroviruses is 
needed. 
Consequently, the current study had two focus points: First, the study focused on 
developing and optimizing methods for sensitive and specific detection of 
enteroviruses in cell and tissue samples. Sensitivities of these methods were also 
compered to each other. These tasks included the development of novel 
enterovirus-specific probe sets for the commercially available ISH technique. The 
lack of type-specific identification of enteroviruses from the pancreas of T1D 
patients has hindered the progress in this field, but the present study shows that 
ISH technology, coupled with careful optimization of probe sequences, can be used 
to detect enteroviruses in type-specific manner. The second focus area was to apply 
some of these detection methods to human tissue samples to evaluate possible 
presence of enteroviruses. Differences in the anti-viral response in the pancreas of 
T1D and control subjects were also addressed. 
6.1 Custom enterovirus probe set design and detection spectrum 
The first paper describes a specific RNA-based method for the detection of 
enteroviruses in FFPE samples. This kind of method could allow exact localization of 
the virus and, thus, would be useful in evaluating the role of enteroviruses in T1D 
pathology. The aim was to create a group and type-specific detection methods for 
enterovirus species A and B and for a single enterovirus type, CV-B1, that has been 
linked to T1D in epidemiological studies (113,126). This was enabled by careful 
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analysis of viral genomic sequences for the design of optimal QuantiGene® ViewRNA 
ISH probe sets.  
The results demonstrated that the QuantiGene® ViewRNA ISH technique can be 
used to detect enteroviruses in FFPE samples. Different approaches were applied in 
the design of the probes, which also reflected the recognition spectrum of the probe 
targets. The most conventional approach based on a continuous sequence from a 
single viral strain, resulted - not surprisingly - in the narrowest enterovirus 
recognition. In other words, the CVB1Sub probe recognized only CV-B1s, which in 
that way makes it a type-specific probe. However, CVB1Sub did not recognize all the 
CV-B1 strains tested nor did it recognize all the CV-B1 strains in an equal manner. 
This is not surprising, since the target sequence covered continuous sequence from 
the VP1 and VP3 structural regions of one CV-B1 strain (I, Supplementary, Table 5.), 
while sequence variation occurs also between the strains within one single virus 
type. The results seemed quite logical, as the QuantiGene® ViewRNA ISH requires 
around 80-85% sequence coverage for the signal to be produced, i.e., approximately 
80% of the target sequence has to be recognized by the probe sets (information 
obtained from Affymetrix).  
The EV B probe was designed to recognize enteroviruses mainly from species B. 
Again, only one CV-B1 strain sequence was used for the design, but this time, instead 
of choosing a continuous sequence, only the most conserved parts from the P1 
region of the genome were used. This probe showed how conserved some regions 
of enteroviruses are, since the probe was able to recognize all the 20 tested species 
B virus types. A further step was taken with the design of the EV AB probe, which 
recognized all tested enteroviruses from species A, B and C with better coverage 
and stronger staining intensity compared to EV B probe. EV AB was designed by 
choosing consensus sequences from multiple enterovirus types/strains from 
structural and non-structural regions and also by selecting 25% more sequences to 
be included in the probe set. The EV AB probe set was found to be the best probe 
set for broad-spectrum enterovirus detection with QuantiGene® ViewRNA ISH  
system.  
This method is a great tool when the aim is to localize mRNA targets from cells 
and/or tissues when the target in question is abundantly present. Co-staining with 
two different targets that are not expected to co-localize worked also, which is an 
advantage that saves tissue material, reagents and time. However, co-staining of 
two targets that were expected to co-localize in the pancreas gave inconclusive 
results; thus, this technology would need further optimization if used for such 
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purposes. The QuantiGene® ViewRNA ISH technology is also relatively labor 
intensive and prone to variation in assay performance. It is important to be precise 
with temperatures and incubation times, which have a clear impact on the results. 
Conversely, the system offers some flexibility within the different steps of the 
protocol with careful optimization. The QuantiGene® ViewRNA ISH system is also 
relatively expensive to be used for large number of samples.  
6.2 Relative sensitivity of different enterovirus detection methods 
The sensitivity of a virus detection method is fundamentally important when it 
comes to detecting low-abundant targets, such as enteroviruses from human 
samples. As good as the QuantiGene® ViewRNA ISH is in the specificity to detect 
different enteroviruses, the second paper showed that its sensitivity is not optimal 
when the amount of the virus is low in the sample.  
Punctate, intensely stained enterovirus-positive cells can be found within the 
pancreatic islet cells of T1D patients using an anti-enterovirus VP1 antibody (clone 
5D8/1, Dako) (130,140). However, other staining methods, such as ISH or staining 
with other enterovirus antibodies, have failed to confirm the findings (unpublished 
results from nPOD and PEVNET studies).  
In the second paper, a limited dilution series of enterovirus-infected cells was 
created to compare the sensitivity of different methods: A549 cells were infected 
with CV-B1 ATCC strain, and the cells were harvested at different time points post-
infection to have cells that represent different stages of viral replication cycle. An 
FFPE cell microarray block was created for histology. Sections were cut on 
microscopic slides, and all ten samples (negative control, undiluted, and dilution 
from 10-1 to 10-8) were stained at once on the same slide. Frozen samples for RT-
PCR and proteomics were prepared from the same cell aliquots that were used for 
FFPE samples. 
The second paper showed that, overall, all tested methods were able to detect CV-
B1 from the cell samples. However, the sensitivity of these methods varied. RT-PCR 
and proteomics were the most sensitive methods to detect enterovirus in this 
setting. It was also shown that anti-enterovirus VP1 antibody (clone 5D8/1) in IHC 
was the most sensitive staining system tested. There was up to a two-fold log 
difference when compared to the commercial ISH methods used in this study. The 
results of the other enterovirus anti-VP antibodies showed lower sensitivity 
compared to ISH in this particular setting.   
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The proteomics LC/MRM/MS/MS approach is novel in the enterovirus detection 
field. In the second paper, it was the most sensitive method after RT-PCR, reaching 
dilution 10-7. One of its advantages is that the identification and validation 
experiments are performed simultaneously, which ensures that the signals are 
derived from the same peptide and the MS/MS spectrum data can be used for 
protein identification in database searches. It also provides sequence information 
about the detected virus, which in some cases could even specify the virus type in 
the sample. LC/MRM/MS/MS could provide new solutions to identify enterovirus 
infections in chronic diseases, e.g., in pancreatic sections and in blood from patients 
with T1D.  
This study offered a good indication of the relative sensitivities of different methods 
that can be used to detect enteroviruses in infected samples; however, it also has 
limitations. First, it is important to realize that a cell model differs from the actual 
clinical tissue sample where the nature of infection may be different. The infections 
were also performed with only one particular CV-B1 strain, which, in theory, may 
not be recognized equally well in the assays. However, this was most likely not an 
issue, since the antibodies used in IHC and the probes used in RT-PCR and ISH 
recognize a wide range of enteroviruses (I). The proteomics analyses also do not 
depend on the enterovirus type; therefore, it is likely that comparable results would  
be obtained with other enterovirus strains or types.  
All three laboratories, which participated in this study, used the same antibodies in 
the IHC stainings but with different sensitivities. This could be explained by the low 
number of virus-positive cells present in the most diluted samples where the 
number of infected cells may vary from one section to another. This is because the 
virus-positive cells are stochastically distributed at higher dilutions. Therefore, the 
results could be reliable if more sections from the lower dilution samples were 
analyzed. It is also possible that differences in the staining protocols in each 
laboratory, for example, different antigen epitope retrieval approaches or manual 
(Exeter) versus automated staining (Tampere and Uppsala), could have an effect on 
the sensitivity (see Materials & methods, Table 7). Noteworthy, however, was that 
clone 5D8/1 was consistently the most sensitive antibody tested in each laboratory. 
The ISH techniques applied in two different laboratories reached the same 
sensitivity in both laboratories. These two commercial ISH techniques, although 
marketed by different companies, have the same principal and amplification 
technique (45). Consequently, it is logical that comparable results were obtained. 
PCR and proteomics were used frozen samples, whereas 5 μm thick paraffin samples 
were used for IHC and ISH. Therefore, the sample size in PCR and proteomics was 
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not comparable to that used in IHC and ISH. These limitations also apply to the 
clinical samples, which is why the use of more than one enterovirus detection 
method is recommended to reach optimal specificity and sensitivity. 
6.3 Enterovirus in human tissue samples 
The JDRF nPOD collection analyzed in report III is the largest study series so far used 
to assess enteroviral presence in tissue samples of T1D patients (cadaver organ 
donors with T1D). It is also one of the first studies where up to four different organs 
were analyzed from the same individual. What comes to the enterovirus VP1 IHC in 
the pancreas, this study confirmed the previous findings that the pancreatic islets 
of T1D subjects are more frequently enterovirus-positive compared to non-diabetic 
controls (30,130,131,140), even though enteroviruses were also found in the 
pancreas of one third of the non-diabetic controls. Like insulin-producing beta cells 
in T1D, the VP1 positivity decreased as the duration of the disease increased, which 
is not surprising since enteroviruses have a tropism to insulin-producing beta cells 
(182). Enterovirus VP1 positivity was also analyzed in the exocrine part of the 
pancreas. The positivity was usually seen in ductal-like cells (cell type was not 
identified by cell-specific markers), but no significant differences were observed 
between the donor groups (positivity rate ranged from 36% to 43 %, data not 
shown).  
Enterovirus positivity was found also in the duodenum and spleen, and positivity 
rate was higher among T1D donors compared to non-diabetic controls. However, in 
the spleen there was only a tendency towards this direction that was not statistically 
significant. The duodenum, however, showed a marked difference in the 
enterovirus positivity of T1D and AAb+ donors compared to controls. Moreover, 
when comparing the enterovirus positivity between different organs, it was 
observed that T1D and AAb+ donors were more often enterovirus-positive in 
multiple organs compared to control donors. Frequent detection of enteroviruses 
in multiple organs in T1D patients compared to control subjects supports the idea 
that T1D is indeed associated with an enterovirus infection. The beta-cell specific 
expression of enterovirus protein together with the higher prevalence of the virus 
in T1D patients suggests that the infection may play a role in the pathogenesis of 
T1D. Conversely, it is also possible that diabetes may indirectly increase the 
susceptibility to enterovirus infection, e.g., by affecting the immune system. 
However, the fact that also the AAb+ (and still non-diabetic) subjects were more 
                 71 
frequently virus-positive than controls argues against this possibility. One reason for 
the higher enterovirus positivity rate in the T1D group could be related to the 
proinflammatory milieu created by the autoimmune process (65,183) which, in 
theory, could make the organs susceptible to the virus and facilitate its spread to 
multiple organs.  
Interestingly, an inverse association existed between enterovirus positivity in 
pancreatic islets and duodenum in T1D donors, as individuals with shorter duration 
of T1D were more often enterovirus positive in the pancreas, whereas individuals 
with longer duration were more often positive in the duodenum. The higher 
prevalence of the virus in the duodenum of T1D and/or AAb+ donors compared to 
control donors is in line with the previous findings (29,132). The small intestine is 
the primary replication site of enteroviruses; therefore, this finding can reflect a 
higher frequency of acute or chronic enterovirus infections in T1D patients. 
However, it is also possible that the duodenal mucosa of T1D patients is abnormally 
permissive for enteroviruses. T1D is a multi-organ disease affecting not only the 
pancreas but also the gastrointestinal tract. Reports suggest that many diabetic 
patients suffer from gastrointestinal disorders or diabetic enteropathy, which has a 
largely unknown ethiopathogenesis (184). Patients may suffer from abnormalities 
in the gut mucosa and altered gastrointestinal motility, which can cause a variety of 
symptoms, and be associated with intestinal inflammation, in T1D patients. This 
dysfunctional intestinal homeostasis may worsen over time, perhaps making the 
intestine more prone to viral infections in patients with long T1D duration. However, 
AAb+ donors were also frequently enterovirus-positive in the duodenum, 
suggesting that the diabetes process per se is not critical in this phenomenon.  
Enteroviruses were more common in tissues of T1D donors compared to control 
donors. However, these results do not directly indicate whether the virus was there 
before the onset of T1D or whether the tissue was more prone to infection due to 
the T1D associated changes. It is possible that enteroviruses infect islet beta cells in 
the pancreas at any age and any stage of the diabetic process, possibly even several 
times during the lifespan. For example, enteroviruses were frequent in the pancreas 
of AAb+ donors who were still non-diabetic. In addition, enterovirus infections may 
also accelerate the progression of islet autoimmunity as suggested by frequent 
detection of enteroviruses at the onset of clinical T1D in retrospective studies (114) 
and accelerated progression of the beta-cell damaging process in enterovirus 
positive children in prospective studies (123) .  
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As mentioned earlier, several studies have suggested that enteroviruses have 
tropism to beta cells. From this point of view, one of the most important findings is 
that enteroviruses can infect and damage beta cells and induce inflammatory 
infiltrates in lethal enteroviral infection in children in the absence of T1D (185). This 
suggests that T1D-associated changes in the pancreatic islets are not associated 
with virus tropism, which instead may simply be a natural biological feature of 
certain enteroviruses. The mechanisms of tropism may be related to the expression 
of viral receptors in beta cells as the main receptor of CV-B is strongly expressed by 
these cells (163). In addition, ability of a single cell to mount innate immune 
responses can significantly modulate the tropisms of enteroviruses. In fact, it has 
been shown that enteroviruses cause rapid beta-cell damage in transgenic mice, in 
which beta-cells do not produce interferons (186) and in which the innate immune 
system response to the virus is lower in beta-cells than in alpha cells (78). In the 
present study, the subjects with T1D, especially at or near the onset of diabetes, had 
more enterovirus VP1-positive cells per islet compared to control subjects 
suggesting that the virus can spread wider in the islets of T1D patients.  
Interestingly, enterovirus was detected also in the spleen, even though the 
difference between T1D patients and controls was not as clear as in the pancreas 
and duodenum. The spleen is an organ that has been referred to as “the filter of the 
blood” due to its extensive vascularization and the presence of macrophages and 
dendritic cells that remove microbes and dying red blood cells from the blood. Other 
functions of the spleen include antibody synthesis and reservoir of blood cells 
(187).Thus, the presence of enteroviruses in spleen may reflect ongoing or recent 
infection in other organs or anatomical sites, and transport of the virus to spleen via 
blood, possibly by infected leukocytes. It is not known how long the virus could 
persist in the spleen after the acute phase of the infection. The relatively high 
frequency of virus-positive cases suggests that enteroviruses may stay in spleen for 
quite a long time.  
RT-qPCR was performed on 230 different samples. These included samples from the 
pancreas, duodenum, spleen and PLN from 90 different donors from three different 
donor groups (from 41 T1D, 17 AAb+, and 32 control donors). Tissue samples were 
either snap-frozen or stored in OCT or RNALater. When only small amounts of tissue 
samples were available, a so-called tissue slab of the sample was analyzed, which in 
this study was approximately a 50-μm thick section cut from the frozen OCT tissue 
sample. The majority of the duodenum samples analyzed were tissue slabs, and 
duodenum was also the only organ in which this kind of samples were available. As 
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it turned out, all the duodenum samples were enterovirus-negative in RT-qPCR, but 
many of them were positive for enterovirus VP1 protein in IHC. The reason for this 
discrepancy is unknown, but several options can be speculated. First, when organs 
are collected, most of them go through the perfusion process to better preserve the 
integrity of the organ (188). With the nPOD samples, the intestine, however, does 
not go through this; therefore, it is subject to autolysis and other degrading 
processes. As is well known, RNA is very unstable compared to proteins, and at 
conditions present at organ collection, it is possible that viral RNA is degraded by 
numerous RNases and other degrading enzymes (189,190). Second, it is even more 
unlikely to find viral positivity, as many of the duodenum samples analyzed were 
only 50-μm thick tissue slabs, meaning dramatically smaller-sized samples and, thus, 
including less RNA compared to the ‘normal’ sized tissue piece (at least 2 mm x 2 
mm). Another aspect to consider is that the analyzed samples may contain 
substances that inhibit PCR reaction, and thus have an effect on the assay sensitivity 
(191-193). 
From the altogether 230 analyzed samples, 23 were positive for viral RNA (15 
pancreas, 2 PLN and 6 spleen samples). Enterovirus-positive samples came from all 
donor groups, but the numbers were too small to make any comparisons between 
the groups. One T1D case was enterovirus positive in the pancreas, spleen and PLN, 
and another T1D case in the pancreas and spleen. All the other enterovirus-positive 
samples came from different donors, in other words only one organ was positive for 
the virus. It is also important to note that not all four organs were analyzed from 
every donor. Further studies are needed to verify the presence of enterovirus in 
these organs, and such studies are currently ongoing in the nPOD-Virus community. 
The samples analyzed in RT-qPCR and IHC represent a tiny part of the whole tissue 
and it would therefore be optimal to analyze multiple tissue regions. Unfortunately, 
this is not always possible due to the limited amount of tissue material.  
Although more enterovirus positivity can be found in T1D organ donor tissues 
compared to control donors, causality cannot be based only on staining results. 
Donors with diabetes-related autoantibodies but without the overt disease might 
be the most interesting group to study when examining the mechanisms operating 
before the disease onset. In this particular group the more you have the 
autoantibodies, the higher is the risk of the disease (73). Therefore, the best group 
to study would be the individuals with multiple autoantibodies. The challenge is that 
tissue samples are only rarely available from such cases. 
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6.4 Immune response to viral infection 
As previously discussed, the host response to the virus may contribute to virus–
induced beta cell damage and determine whether the infection leads to an 
autoimmune-like process in the islets (Chapter 2.5). Therefore, organ donors that 
were enterovirus VP1-positive in the pancreas, including donors from T1D, AAb+ 
and control groups, were further analyzed for the expression of selected markers 
that reflect the host immune responses against viral infection in the pancreas. The 
aim was to find out whether their expression in enterovirus VP1-positive islets 
differs between the donor groups. This study included altogether 31 VP1-positive 
organ donors (12 T1D, 7 AAb+ and 12 control donors).  
The most striking difference between the donor groups was observed in class I HLA 
expression as all T1D donors expressed elevated levels of HLA I across the 
enterovirus VP1-positive islets, whereas all control donors had normal class I HLA 
levels in enterovirus-positive islets. This finding is in line with previous publications 
(143,160,194). Richardson et al described the HLA I hyperexpression as a hallmark 
of immunopathogenesis of T1D (160). They observed that HLA I levels were clearly 
elevated both at protein and RNA levels in insulin-containing islets of T1D patients. 
β2M- and STAT1 expression levels were also increased. In addition they observed 
that islet hyperexpression of HLA I molecules is detectable in many T1D patients for 
up to 11 years of disease duration, after which it starts to decline.  
In the present study, MxA was also overexpressed in the islets of all T1D and AAb+ 
donors but in none of the control donors. MxA gene is IFN-regulated protein and 
induced by type I and type III IFNs but not by type II IFN or other cytokines. The MxA 
protein is considered an important component of the innate immune defense in 
humans (157) possessing intrinsic antiviral properties. Thus, these results clearly 
suggest that the local immune response is more strongly activated in the 
enterovirus-positive islets in T1D patients than in controls and that it involves 
interferon-mediated responses. This unique finding supports the concept that host 
response to the virus may be an important factor in virus-induced beta cell damage 
(78,195). Antiviral responsiveness is regulated by genetic factors, including genes, 
which are associated with the risk of T1D (see below). The present study showed no 
difference in the protein kinase R (PKR) expression between the donor groups. PKR, 
which is induced directly by dsRNA but also through type I IFNs, was positive in 
enterovirus VP1-positive cells regardless of the donor group. Increased PKR levels 
were associated with reduced insulin immunopositivity in individual beta cells, 
which is consistent with possible induction of host protein translational arrest by 
PKR or by viral proteases (196-198).  
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Based on the differences in class I HLA expression in T1D and control organ donors, 
it can be speculated that individuals at risk of T1D may have an inherited tendency 
to strong IFN responses, which amplifies inflammatory signals that ultimately lead 
to autoimmunity and disease development. Innate immune response pathways are 
partly regulated by SNPs, such as those in TYK2 and IFIH1 genes. Different genotypes 
in these SNPs could ultimately lead to either rapid disease development or offer 
protection from the disease (77,79,199). It has been suggested that TYK2 regulates 
apoptotic and proinflammatory pathways in beta cells by modulating IFN-α 
signaling, which subsequently increases HLA I protein expression and modulates 
chemokines such as CXCL10. To support this, chemokines, such as CXCL10, have 
been found to be increased in the pancreatic islets after enterovirus infection (148-
150). Thus, it is possible that these SNPs can lead to more pronounced IFN-response 
in virus-infected T1D subjects. Analogously, human beta cells that have been 
silenced for TYK2 show decreased type I IFN pathway activation and lower 
production of IFN-α when exposed to dsRNA mimic polyinosinic-polycytidylic acid 
(PIC) (77). In addition to SNPs, the T1D-associated HLA-DR risk and protective alleles, 
respectively, have been shown to be associated with stronger (risk alleles) and 
weaker (protective alleles) immune responsiveness against enteroviruses (200). 
Therefore, it is possible that virus-gene interactions can also explain the observed 
differences in islet antiviral response in T1D patients and controls.  
The present study suggests that an enterovirus infection in the pancreatic islets may 
contribute to the upregulation of PKR, HLA I and MxA in islets of T1D patients. 
However, this does not completely rule out the possibility that other viral infections 
are also present in the pancreas, partly causing these phenomena. PKR upregulation 
was always seen in cells that were enterovirus VP1-positive. In some cases, 
however, PKR positivity was also observed without VP1 presence. PKR is activated 
by dsRNA, which is produced during enterovirus replication in the infected cell. 
However, other viruses can also produce dsRNA. It has been reported so far that at 
least influenza A viruses can grow in human pancreatic cells and cause pancreatitis 
and diabetes in an avian animal model. In that particular study, the virus was also 
able to infect human pancreatic islets (201). Rotavirus infection has also been 
associated with pancreatic islet autoimmunity through molecular mimicry (202). 
Rotaviruses have also been shown to infect the pancreatic islets in various animal 
models (203). However, rotavirus itself has not been directly found in human 
pancreatic islets. In addition, some other viruses could also infect beta cells, 
including adenoviruses (Ads) that use CAR as their receptor for cell entry (such as 
Ad 2, 4, 5, 15, 19p, 31 and 41 (204); however, adenoviruses have not yet been found 
in the pancreas. Ad 41 has tropism to the intestine, which is anatomically closely 
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related to the pancreas; therefore, it can be speculated that, like enteroviruses, it 
may also find a route to pancreas. 
6.5 Causality of EV – type 1 diabetes association 
Do enteroviruses cause T1D or are they just a consequence of pathological 
manifestations of the disease? Do enteroviruses appear stochastically, and/or is 
there a yet-to-be-resolved confounding factor that has its effect on enterovirus 
appearance in tissue samples? These are not easy questions to answer, nor is the 
answer most likely a simple ‘yes’ or ‘no’. Causality is difficult to prove, especially if 
intervention trials have not been carried out. Additionally, factors that are causing 
the disease in certain populations might not do so in all other populations. The 
population genetics, environmental factors and epidemiological patterns, such as 
demographical, biological, geographical and other factors in populations, may play 
a role in disease development and onset (205). Therefore, while many times results 
from a given population can be generalized to wider populations, one must 
remember that certain populations may be more susceptible to disease 
development than others.  
As mentioned earlier, T1D is most likely a disease with multiple origins; therefore, 
enteroviruses may not be the causative agents in all disease forms. The cumulative 
evidence of a link between enteroviruses and T1D is, however, strong and 
repeatedly documented. Consequently, it seems likely that enteroviruses could play 
a role in at least part of T1D cases. This is also supported by the fact that the majority 
of T1D patients are positive for enterovirus in the pancreatic islets. On the other 
hand, the “hygiene hypothesis” suggests that the decreasing incidence of infections 
in developed countries could be a major driving force behind the increasing 
incidence of allergies and autoimmune diseases including T1D (169,206,207). 
Multiple approaches are needed to understand these relationships. Interventions, 
most obviously vaccination, could directly demonstrate the causality of infections. 
6.6 Relevance of tissue studies 
This doctoral thesis focuses on pancreatic studies, and more specifically on 
immunohistochemical stainings. Pancreatic studies, however, can be carried out 
using various kind of approaches. While histological stainings identify viral proteins,  
RT-PCR identifies the presence of viral nucleic acid, which can be further studied by 
sequencing the amplified genome region. Sequencing may reveal which viruses or, 
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more likely, which virus families are present in the tissue. Laser-captured 
microdissected islets can be studied to evaluate possible islet origin of the virus 
accompanied by other analyses such as gene expression analyses (160). The 
sensitivity of the assays used to detect infection in target tissue depends on the 
assay technology and the quality of the sample. For example, fixation of the tissue 
has a major effect on virus detection by immunostainings, and the details of the 
fixation process need to be taken into account when selecting optimal assays for 
enterovirus detection (e.g., fixation solution, duration of fixation, paraffin 
embedding). The storage condition and the expected amount of virus in the sample 
may also influence the results. (134,208)  
As shown in paper III, enteroviruses can spread to different organs. This is in line 
with previous human studies and mouse models of enterovirus infection. Murine 
studies have shown that enteroviruses infect multiple organs and that the affected 
organs vary between mouse strains and the virus type in question ((209); 
unpublished data from nPOD-Virus community). The same applies to humans: 
Certain enterovirus types or strains can infect certain organs. However, it is 
challenging to type the virus in the tissue using histological techniques due to lack 
of reagents that specifically and sensitively could recognize enteroviruses from 
tissues in a type-specific manner. On the other hand, sequencing of the viral genome 
that has been amplified by RT-PCR from tissue sample can provide information 
about the type of enterovirus present. The sensitivity of RT-PCR is critical for the 
success of this approach. 
Prospective cohort studies have a great advantage compared to pancreas tissue 
studies since they make it possible to deduce at which point of lifespan there is an 
excess of infections and what is the temporal relationship of these infections to 
possible emerging autoantibody seroconversion and onset of T1D. For example, an 
excess of enterovirus infections has been found prior to autoantibody 
seroconversion by detecting enterovirus RNA in serial serum and stool samples 
collected from prospectively followed children in the Finnish DIPP study (22,112). 
These infections thus precede the activation of the process leading to T1D. 
However, prospective studies cannot provide information about the spread of the 
virus to different organs, and its possible persistence in the pancreas. Thus, 
information from tissue studies and clinical cohorts supplement each other and 
their combination offer an ideal approach to understand the pathogenesis of T1D.  
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6.7 Enterovirus persistence  
Enterovirus persistence in the pancreas is currently one of the key hypothesis to 
explain the development of virus-induced T1D. Enteroviruses are considered 
cytolytic viruses but they are also able to establish persistent infections in vitro and 
in vivo (210,211). Persistence of a virus may lead to an inflammatory process, which 
in turn can contribute to the induction of autoimmune responses (212). Some 
enteroviruses may persist in the central nervous system (CNS) and, thus, avoid 
clearance by the host (213). Enterovirus persistence in the pancreas has been 
suggested to play a role in the process leading to T1D (212,214,215). Possible 
persistence would fit with the high proportion of T1D patients with enterovirus 
protein in beta cells and low titer of the virus that suggest low-grade rather than 
acute infection (130). In addition, there is no major lytic damage in the pancreata 
where enterovirus has been detected (130,131,140).  
Additionally, it has been proposed that CV-B can persist in the host or host tissue in 
a terminally deleted form in which a deletion occurs in the 5’UTR of the viral 
genome. This leads to a reduced cytopathic effect and reduced viral titers, an 
observation that was first described by Kim et al. in 2008 and later also by Tracy et 
al. in 2015 using murine model (177,178). The low-level replication of persisting 
virus would make it challenging to detect the virus in tissue samples. 
6.8 Future prospects 
Large international studies like nPOD, PEVNET and TEDDY and the Finnish DIPP study 
are vital for the future progress in this field. These studies have already built a basis 
for the concept of intervention studies targeting enteroviruses, such as primary 
prevention by vaccination or secondary prevention by antiviral treatments. These 
intervention studies could provide information about the possible causal nature of 
the enterovirus-T1D association. For example, a finding showing that an enterovirus 
vaccine prevents infections by T1D-associated enterovirus types and decreases the 
occurrence of T1D, would strongly support causality. The first steps have already 
been taken in the vaccine development. Experimental CV-B1 vaccines have been 
highly immunogenic and able to protect mice against a CV-B1 infection and against 
CV-B1-induced diabetes (216). In addition, a polyvalent CV-B vaccine showed a 
similar result (217). These experimental vaccines have not accelerated the 
development of T1D in NOD mice. Moreover, the clinical development of a 
polyvalent CV-B vaccine has started aiming at first human trials in 2020. The ultimate 
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goal is to study whether this vaccine can reduce the incidence of T1D in a phase III 
trial. The fact that poliovirus vaccines have been safe and effective offers a model 
that helps the development process. Enteroviruses are also associated with many 
other diseases, and enterovirus vaccine could offer other advantages beyond T1D 
as well. Antiviral drugs given to patients with T1D-related autoantibodies could 
eradicate the possible chronic infection from the pancreatic islets of these patients, 
possibly improving the function of beta cells and, in the best-case scenario, prevent 
the disease. (218) The first trial to test the effect of antiviral drug treatment 
(combination of pleconaril and ribavirin) on the beta cell function among newly 
diagnosed T1D patients has recently started in Norway (Diabetes Virus Detection 
and Intervention Trial, DiViDinT).  
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Background: Enteroviral infections are common, affecting humans across all age groups. RT-PCR is widely
used to detect these viruses in clinical samples. However, there is a need for sensitive and speciﬁc in situ
detection methods for formalin-ﬁxed tissues, allowing for the anatomical localization of the virus and
identiﬁcation of its serotype.
Objectives: The aim was to design novel enterovirus probes, assess the impact of probe design for the
detection and optimize the new single molecule in situ hybridization technology for the detection of
enteroviruses in formalin-ﬁxed parafﬁn-embedded samples.
Study design: Four enterovirus RNA-targeted oligonucleotide RNA probes – two probes for wide range
enterovirus detection and two for serotype-targeted detection of Coxsackievirus B1 (CVB1) – were
designedandvalidated for the commercially availableQuantiGeneViewRNA in situhybridizationmethod.
The probe speciﬁcitieswere tested using a panel of cell lines infectedwith different enterovirus serotypes
and CVB infected mouse pancreata.
Results: The two widely reactive probe sets recognized 19 and 20 of the 20 enterovirus serotypes tested,
as well as 27 and 31 of the 31 CVB1 strains tested. The two CVB1 speciﬁc probe sets detected 30 and 14 of
the 31 CVB1 strains, with only minor cross-reactivity to other serotypes. Similar results were observed
in stained tissues from CVB –infected mice.
Conclusions: These novel in-house designed probe sets enable the detection of enteroviruses from
formalin-ﬁxed tissue samples. Optimization of probe sequences makes it possible to tailor the assay
for the detection of enteroviruses on the serotype or species level.
© 2015 Elsevier B.V. All rights reserved.
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1. Background
Enteroviruses1 (EVs) often cause mild, common ﬂu-like symp-
toms, but they can also be responsible for more severe conditions,
such as myocarditis, central nervous system infections and
poliomyelitis [1]. Currently, the over 110 human EV serotypes are
divided into four species termed Enterovirus A–D. Increasing evi-
dence suggests that these different EV serotypes play a role in the
1 EV, enterovirus.
http://dx.doi.org/10.1016/j.jcv.2015.06.085
1386-6532/© 2015 Elsevier B.V. All rights reserved.
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pathogenesis of acute [2,3] and chronic diseases; e.g., EVs of species
B have been linked to the pathogenesis of myocarditis [4,5] and
type 1 diabetes2 (T1D) [6,7]. Current evidence also suggests that
EVs can establish a slowly replicating persistent infection in the
pancreas [8,9]. Furthermore, recent epidemiological studies have
suggested that some group B coxsackieviruses3 (CVBs), belonging
to theEVBspecies, are linked to the initiationofpancreaticbeta-cell
autoimmunity and development of T1D [10,11]. The causal associa-
tion between EVs and T1D however, remains uncertain and further
studies are needed to verify this question.
The interest in the direct detection of EVs in their target organs
has increased in the last fewyears. Theseviruseshavecaused severe
epidemics (e.g., those with CVB1, EV68 and EV71) and place an
increasing burden on society. While RT-PCR allows for the sensi-
tive detection of EVs in clinical samples, it does not work optimally
in formalin-ﬁxed parafﬁn embedded4 (FFPE) tissue samples and
can also not be used for the localization of the virus in speciﬁc cells.
In fact, a method capable of detecting a broad range of EVs and
distinguishing individual serotypes directly in FFPE tissue samples
has not been reported. Methods suited for EV detection in FFPE
samples would offer important advantages: (1) most tissue sample
collections are based on FFPE samples (2) such samples preserve
the histological structures. Thus far, immunohistochemistry-based
studies on EVs have mostly been based on a single commercially
available antibody clone 5D8/1 (Dako, Glostrup, Denmark) that rec-
ognizes viral capsid protein VP15 [12]. This method has provoked
discussions with regards to its sensitivity and speciﬁcity in recent
publications [13–16]. Combining viral protein ﬁndings with stan-
dardized and reliable in situ hybridization6 (ISH) mRNA results
would strengthen the reliability of viral detection. Further, as EV
serotypes have different pathogenic features, there is a clear need
for a standardized method capable of distinguishing these viruses;
not only species-speciﬁcally but also group- or serotype speciﬁ-
cally.
The challenges posed with detecting viruses using ISH, espe-
cially RNA viruses such as EVs, include the lack of a common
nucleotide sequence in all viruses, high sequence variation and
genomic recombination. Nevertheless, these characteristics also
enable both narrow and broad genotypic detection design for
various EVs. Firstly, different gene regions common in varying
taxonomic levels can be utilized in a speciﬁc probe design depend-
ing on how broad the genotype detection is wanted. Secondly,
loci of the target probe sequences can be selected from genomic
regions with either high or low variation and thirdly, the design
of the probe sequence can be based on either a single geno-
type sequence or a consensus sequence of various enteroviral
genomes.
2. Objectives
The aim of this study was to broaden the methods available
for EV detection in tissue samples. We developed a novel speciﬁc
ISH method for selected EV species, as well as serotype-speciﬁc
assays, using a commercial and standardized non-radioactive
Affymetrix QuantiGene ViewRNA system for FFPE cell and tissue
samples.
2 T1D, type 1 diabetes.
3 CVB, group B coxsackievirus.
4 FFPE, formalin-ﬁxed parafﬁn-embedded.
5 VP, viral protein.
6 ISH, in situ hybridization.
3. Study design
3.1. Enterovirus-infected cell culture samples
Green monkey kidney cells (GMK and Vero), carcinomic human
cervix epithelial cells (HeLa), carcinomic human alveolar basal
epithelial (A549) cells and human rhabdomyosarcomamuscle cells
(RD) were grown in a monolayer in complete media (Supplemen-
tary, Table 1)with 5% FBS. The cell lineswere infectedwith selected
viruses (Supplementary, Table 2 and 3) in their individual T75 ﬂask,
until 50% cytopathic effectwas reached, then harvested by scraping
and ﬁxed in 4% formaldehyde in PBS for 24–72h prior to dehydra-
tion and parafﬁn embedding.
3.2. Animal husbandry and in vivo CVB infections in mice
Non-obese diabetic7 (NOD) and C57BL/6J Rag−/− (B6 Rag-/-)
mice were bred and housed in a speciﬁc-pathogen-free environ-
ment at Karolinska Institutet, Stockholm, Sweden. All mice were
infected through the intra peritoneal (i.p.) route with different
serotypes and doses of CVBs diluted in 200l RPMI (Supplemen-
tary, Table 4). Plain RPMI was used for mock-infected controls.
Systemic infection was conﬁrmed in blood by RT-PCR or plaque
assay on day 3–5 post infection. Organs were harvested between
day 3 and 7 post infection and ﬁxed in 4% formaldehyde in PBS
for 24h prior to dehydration and parafﬁn embedding. All animal
experiments were approved by a local ethics committee and con-
ducted in accordance with the NIH principles of laboratory animal
care and the Swedish law.
3.3. Probe set design
Characteristics of the EV genome were utilized in the optimiza-
tionof theprobe speciﬁcity. Twodifferent probe setsweredesigned
for individual EV serotype, namely probes CVB1 and CVB1Sub and
two for species-speciﬁc detection, namely probes EV AB and EV B
targeting mainly EV species A and B and EV B, respectively. The
design was based either on a sequence of one viral strain (probes
CVB1Sub and EV B) or on a consensus sequence of multiple viruses
(probes CVB1 and EV AB). The CVB1Sub probe was designed based
on a sequence in GenBank under the accession no. EU147493.1 and
that of probe EV B on the accession no. KJ849619. For the probes
where the design is based on a consensus sequence, all of the avail-
able full-length EV sequences in GenBank were used (28 sequences
for CVB1 probe and 128 sequences for EV AB probe). In addition for
CVB1 probe, the P1 region of 27 wild type CVB1 strains circulating
in Europe, South- and North-America were sequenced. All these
sequences were aligned using the Clustal X program. Analogous
sequences were deleted to avoid the possible over impact of mul-
tiple similar sequences on the consensus sequence of the aligned
CVB1 strains. The consensus sequence was extracted and used as a
template for probe design.
The sequence of P1 region of the EV genome links to viral
serotype, hence this locus was used solely as the serotype-speciﬁc
probe targets (probes CVB1 and CVB1Sub). The 5’ untranslated
region8 (UTR) is common between A and B species and similarly
between C and D species, whereas P2 and P3 regions are relatively
conserved within all EV species. To target probes at species level
(probes EV AB and EV B) and to maximize the sensitivity, the con-
served regionsof5′UTR, and, conserved loci fromthenon-structural
P2 and P3 regions were used (Fig. 1, Table 1). Oligonucleotide
7 NOD, non-obese diabetic.
8 UTR, untranslated region.
J.E. Laiho et al. / Journal of Clinical Virology 69 (2015) 165–171 167
Fig. 1. Schematic presentation of the EV genomic structure. The positions of probes in the EV genome are marked with black lines.
Table 1
Description of the enterovirus probe sets.
Probe name Target region length Main target Viral sequences used for probe design
EV AB 1359 Species A, B Consensus sequences from
- P2 and P3 regions of EV A
- 5′UTR, P2, P3 regions of EV B
EV B 1063 Species B GenBank accession no KJ849619
- 5′UTR, P2, P3 regions
CVB1 908 CVB1 strains Consensus sequence of CVB1 strains from P1 region
CVB1Sub 960 Genetically close strainsof CVB1 EU147493 GenBank accession no EU147493 from P1 region
fragments from 33 to 51 nucleotides9 (nt) long were selected (Sup-
plementary, Table 5). Depending on the probe, these probe set pair
fragments formed, as a whole, a target sequence with the length of
908 to 1359 nt (Table 1).
3.4. Quantigene ViewRNA in situ hybridization
TheQuantigeneViewRNA ISH system is based on a similar probe
set design and the branched DNA signal ampliﬁcation technology,
as the previously described RNAscope ISH [17], providing robust
in situ detection of target mRNA from FFPE sections with single-
copy sensitivity. The assay itself can be divided into four primary
steps: sample preparation, target hybridization, signal ampliﬁca-
tion and detection with brightﬁeld and/or ﬂuorescent microscopy.
Viral RNA was stained and visualized in 5-m parafﬁn-
embedded sections from acutely enterovirus-infected cell culture
samples and CVB-infected mouse pancreas according to the man-
ufacturer’s instructions. Brieﬂy, FFPE sections were rehydrated,
pretreated by 5min boiling and incubated with Proteinase K
(5g/ml in PBS) for 10min. They were subsequently incubated
with a viewRNA probe set designed against the mRNA of CVB1,
or against the mRNA covering the conserved regions of Enterovirus
B species (i.e., EV B probe set) or against themRNA of the conserved
regions fromEVA&B species (i.e., EVABprobe set). After incubation
the signal was ampliﬁedwith alkaline phosphatase10 (AP) –labeled
probes and visualized under both brightﬁeld and ﬂuorescent light
with objectives UplanFL 10X/0.30, UplanFL 20X/0.50, and UplanFL
40X/0.75, and an Olympus BX60 ﬂuorescent microscope (Olympus,
Melville, CA, USA).
3.5. Immunostaining with clone 5D8/1
Immunostaining with clone 5D8/1 (Dako, Glostrup, Denmark)
to detect enterovirus capsid protein 1 (VP1) in cells was performed
as previously described [18]. For murine tissue, FFPE pancreatic
sections were cut into 5-m sections and stained as previously
described [19], with the following modiﬁcations; antigen retrieval
was performed in 10mM Tris and 1mM EDTA, pH9, and sections
9 nt, nucleotide.
10 AP, alkaline phosphatase.
were stained using a biotinylated clone 5D8/1 antibody (biotiny-
lated by Capra Science, Ängelholm, Sweden).
All the stained slides were further analyzed using scanned
slide images. The slides were scanned with a fully automated
Objective Imaging Surveyor virtual slide scanner. Digitization was
performed at a resolution of 0.4 microns per pixel (using 20X Plan
Apochromatic microscope objective). Image data was converted to
JPEG2000 format as previously described [20].
4. Results
The ability of the newly designed probe sets to bind their target
mRNAs was examined using infected and non-infected cell lines,
including a variety of different EV serotypes and strains (Supple-
mentary, Table 2 and 3) and pancreas samples collected from mice
infectedwithCVBserotypes1, 3, 4, 5and6. The results aredescribed
in a table format valuing the binding to the mRNA target as fol-
lows: −=no binding; + =weak positive; ++ =positive; +++= strong
positive (Tables 2–4).
4.1. Detection of enteroviruses in infected cells
TheEVABprobe recognized all tested viruses of EV speciesA and
B. The recognition spectrum of EV B probe was similar to that of EV
AB probe, with the exception of poliovirus 311 (PV3) which belongs
to EV species C; however, the overall intensity of the staining of
different serotypes was stronger with the EV AB probe (Fig. 2.).
The CVB1 probe stained all but one CVB1 strains strongly, but also
reactedweaklywith someother CVB serotypes. TheCVB1Subprobe
gave a more narrow recognition spectrum among the tested CVB1
strains and it did not react with any other serotype. Every probe
gave a negative result in the mock-infected cells as well as in the
human parechovirus112 (HPeV1) and Adenovirus C infected cells
(Tables 2–4).
11 PV3, poliovirus 3.
12 HPeV1, human parechovirus 1.
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Table 2
Probe sets’ recognition spectrum of various EV serotypes and control viruses. Binding of monoclonal antibody against EV VP1 is shown for comparison.
Virus Probe sets Anti-VP1 antibody
Species Serotype EV AB EV B CVB1 CVB1Sub Clone 5D8/1
EV B CVB1 +++ +++ +++ +++ +++
EV B CVB2 +++ ++ – – +++
EV B CVB3 +++ ++ – – +++
EV B CVB4 +++ ++ + – +++
EV B CVB5 +++ +++ – – +++
EV B CVB6 +++ ++ – – ++
EV B Echo3 +++ ++ – – +
EV B Echo4 +++ +++ – – +
EV B Echo6 +++ +++ + – +++
EV B Echo9 +++ ++ – – ++
EV B Echo11 +++ ++ + – +
EV B Echo30 +++ ++ – – +++
EV B CVA9 +++ ++ – – +++
EV A CVA2 ++ + – – +
EV A CVA4 ++ ++ – – +
EV A CVA5 + + – – ++
EV A CVA6 ++ + – – +
EV A CVA10 +++ ++ – – +
EV A CVA16 +++ ++ – – +
EV A EV71 – – – – –
EV C PV3 ++ – – – ++
Adeno VR846 – – – – –
HPeV HPeV1 – – – – –
4.2. Detection of group B Coxsackieviruses in infected mice
Theprobes’ ability to recognize their targets inpancreas samples
from CVB infected mice was also tested. Every probe gave a posi-
tive signal when detecting their matching targets. The recognition
pattern followed that seen in infected cell culture samples (Fig. 3).
Some cross-recognition was observed with CVB1 probe, which also
bound to CVB5 and weakly to CVB3 (Table 4).
5. Discussion
The results of the present study demonstrate that new single
molecule ISH techniques can be used to detect EVs in FFPE samples.
This technology also offers certain advantages over traditional ISH
methods, as it is based on non-radioactive probes and as the ﬂex-
ible probe design enables the detection of either a wide range of
different virus types or the identiﬁcation of the exact serotype of
Table 3
Probe sets’ recognition spectrum of different CVB1 strains. Binding of monoclonal antibody against EV VP1 is shown for comparison.
CVB1 Strain Probe sets Anti-VP1 antibody
ID Place Year EV AB EV B CVB1 CVB1 Sub Clone 5D8/1
PB-10787 GA, USA 1970 +++ – + +++ +++
PB-10789 ME, USA 1972 ++ + – ++ ++
PB-10790 TN, USA 1973 ++ ++ ++ +++ +++
PB-10791 NH, USA 1977 ++ + + + ++
PB-10792 ME, USA 1979 ++ + ++ ++ ++
PB-10794 SD, USA 1981 ++ ++ + – ++
PB-10796 Argentina 1983 +++ + + Not analyzed ++
PB-10798 GA, USA 1985 +++ ++ +++ + +++
PB-10799 Honduras 1987 +++ ++ ++ +++ +++
PB-10800 TN, USA 1991 +++ ++ +++ ++ +++
PB-10802 Argentina 1998 +++ ++ +++ – +++
PB-10803 Chile 1998 +++ +++ + – +++
PB-10788 ME, USA 1971 +++ ++ ++ ++ +++
PB-10793 RI, USA 1980 +++ ++ +++ + +++
PB-10795 GA, USA 1982 +++ ++ ++ + +++
PB-10797 CT, USA 1984 +++ ++ +++ – +++
PB-10801 South Africa 1992 +++ ++ ++ – +++
PB-5CWCS COL, USA 2007 +++ ++ +++ – +++
PB-59XGU GEO, USA 2007 +++ +++ ++ – +++
PB-5HTTV GEO, USA 2008 ++ + ++ – ++
PB-5HJXX Germany 2008 +++ + +++ – +++
PB-59MG4 WAS, USA 2008 +++ +++ +++ – +++
PB-5FAMZ WAS, USA 2007 ++ ++ +++ – +++
PB-59ZJJ GEO, USA 2008 +++ ++ +++ – +++
ATCC +++ + ++ ++ +++
PB-CVB1V200 No data No data +++ – ++ +++ +++
CF217010 FRA08 France 2008 ++ ++ +++ – ++
CF1650 FRA02 France 2002 ++ + +++ – +++
CF741 FRA93 France 1993 + + ++ – +
CF1887 FRA00 France 2000 +++ – +++ – +++
CF168014 FRA06 France 2006 +++ – ++ – +++
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Table 4
Probe sets’ recognition spectrum of CVB serotypes 1,3,4,5 and 6 infected mouse pancreas. Binding of monoclonal antibody against EV VP1 is shown for comparison.
Virus Mouse Probe sets Anti-EV VP1 antibody
Serotype Strain EV AB EV B CVB1 CVB1Sub Clone 5D8/1
CVB1 V200 NOD ++ ++ ++ +++ ++
CVB1 PB-10796 NOD ++ ++ + ++ ++
CVB1 PB-10802 NOD ++ ++ +++ + +++
CVB3 Nancy B6Rag-/- +++ +++ + – +++
CVB4 E2 NOD ++ ++ – – ++
CVB5 ATCC NOD ++ + ++ – +++
CVB6 ATCC NOD ++ + – – –
Fig. 2. ISH staining in CAV16 infected RD cells. (A) EV AB in infected cells, (B) EV B in infected cells, and (C) EV AB in non-infected cells, red color indicating enteroviral
presence. Panels D, E and F represent the corresponding ﬂuorescent images of A, B and C, respectively. Original magniﬁcation×20. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. ISH staining in infected murine pancreas. CVB3 infected (A), CVB5 infected (B), and non-infected (C) pancreas. Red color indicates enteroviral presence. Panels D, E
and F represent the corresponding ﬂuorescent images of A, B and C. Original magniﬁcation×20.
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virus(es) present in tissue samples, making this technique optimal
for research and diagnostic purposes.
Four different probe sets were designed, two for wide range EV
recognition and two for speciﬁc EV serotype recognition. The most
conventional approach was applied to the design of the CVB1Sub
probe set by choosing a continuous sequence of 960 nt covering
parts of the VP3 and VP1 regions. Consequently, this probe only
detected CVB1 strains. A different approach was selected for the
CVB1 probe set, where conserved parts from the P1 region of a con-
sensus sequence found in many CVB1 strains was used as a basis
for the design. Accordingly, the CVB1 probe detected all but one of
31 CVB1 strains tested. Additionally, sequences from newer circu-
lating strains were prioritized in the CVB1 probe sequence design,
which is also reﬂected in the results by overall weaker recognition
among the older CVB1 isolates (PB-10787 to PB-10796). Despite
the wide serotype-speciﬁc recognition, minor cross-detection of
a small number of other EV serotypes was also observed, particu-
larlyCVB5 (ATCC). In spite of themonotypic recognitionof CVB1Sub
probe, as expected, its recognition spectrum was signiﬁcantly nar-
rower compared to the CVB1 probe. Traditionally, ISH probes are
produced by digesting full-length genomes or long consecutive
regions of one EV strain. Our results show that this kind of probe
(e.g., CVB1Sub) ismore likely to detect a narrow spectrumof genet-
ically similar viruses, therefore making it a non-optimal screening
probe for clinical samples that may be infected with unknown EV
types.
Both of the probes that were originally designed to cover many
EV serotypes recognized a majority of the EV serotypes tested.
Although the original aim behind the design was similar for both
EV AB and EV B probes, the former had a better recognition pro-
ﬁle and stronger intensity of the staining. The main difference
between these probes lies in the design basics; the design of EV
B probe was based on conserved sequence regions of a single
CVB1strain,whereas consensus sequencesofmultiple viruseswere
used for the optimal probe sequence design of EV AB probe. Also,
the overall target length for the latter was approximately 25%
longer, and included more target regions for EV species A, which
is reﬂected in the results by a slightly better recognition of group A
Coxsackieviruses13 (CVAs).
When comparing the recognition pattern of EV AB probe to the
anti-VP1 antibody clone 5D8/1, it was observed that both bind
very well to CVBs and echoviruses. On the other hand, the relative
immunoreactivity of clone 5D8/1 to CVAs is poorer than the tar-
get binding ability of EV AB probe to CVAs (Table 2). Both detected
CVB1 strains equally well (Table 3) and similar results were seen
in infected mice (Table 4). Hence, we conclude that this probe is
a valuable tool for EV detection. However, whether the sensitivity
of EV AB ISH matches that of clone 5D8/1 immunohistochemistry
remains to be conﬁrmed.
In addition to the aspect of sensitivity, detection of viral mRNA
in itself brings challenges, as the viral presence in target tissues is
likely tobevery low.Also, themultipleRNasespresent in the tissues
might have an effect on the results through weakening the signal
by breakingdown the viral RNA.Moreover,mRNAdetection in FFPE
tissues is challenging due to extensive molecular crosslinking that
occurs upon formalin ﬁxation. Regardless of these, we were able to
establish this method on FFPE tissues. Yet, some probe sets might
workevenbetter in frozen sections, ashasbeenpreviously reported
with different antibodies [21].
In conclusion, our results show that the novel probes, together
with the commercial ViewRNA ISH system, enabled the localization
ofmRNA in cell culture and animalmodels and therefore provides a
13 CVA, group A Coxsackievirus.
potentialmethod to study the course of acute viral infections in ani-
mals and humans. Based on these ﬁndings this method can be used
in both the broad screening for EVs and for the identiﬁcation of the
exact serotype of the infecting virus. Also, this strategy is probably
applicable for other viruses when identiﬁcation of the serotype is
required in FFPE samples.
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Background: Enteroviruses  (EVs) have been linked  to the  pathogenesis of several diseases and there  is a
collective  need  to  develop  improved methods for the detection of these viruses  in tissue samples.
Objectives:  This study evaluates  the relative  sensitivity of immunohistochemistry (IHC), proteomics,  in  situ
hybridization  (ISH)  and RT-PCR to detect  one common  EV, Coxsackievirus  B1 (CVB1), in acutely  infected
human  A549 cells in vitro.
Study  design: A549  cells were  infected  with CVB1  and diluted with uninfected  A549  cells to produce
a  limited  dilution  series in  which the  proportion  of infected cells ranged  from  10−1 to  10−8. Analy-
ses  were  carried out by several  laboratories using  IHC with different  anti-EV  antibodies, ISH  with  both
ViewRNA  and  RNAScope systems, liquid  chromatography multiple  reaction  monitoring mass spectrom-
etry  (LC/MRM/MS/MS), and  two  modiﬁcations of RT-PCR.
Results:  RT-PCR was the  most  sensitive  method for  EV  detection  yielding  positive signals in  the  most
diluted  sample  (10−8).  LC/MRM/MS/MS  detected viral  peptides at dilutions as high as 10−7. The sensitivity
of  IHC  depended  on the antibody used,  and the most  sensitive antibody (Dako clone 5D8/1)  detected  virus
proteins  at  a dilution  of 10−6,  while ISH  detected the  virus at  dilutions of 10−4.
Conclusions:  All  methods were able  to  detect CVB1  in infected  A549 cells.  RT-PCR was most sensitive
followed  by LC/MRM/MS/MS  and then  IHC. The results  from this  in  vitro survey suggest  that all methods
are  suitable tools  for EV  detection  but  that their differential sensitivities need  to be  considered  when
interpreting  the  results from  such studies.
©  2016 Elsevier  B.V.  All rights  reserved.
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1. Background
Enterovirus1 (EV) infections are common in all  age groups. They
are usually asymptomatic or cause only mild respiratory symp-
toms, but can also lead to more  severe illness including hand, foot
and mouth disease, myocarditis, meningitis, encephalitis, pancre-
atitis, systemic infection in newborns and paralysis. EV infections
may  also play a role in the pathogenesis of chronic diseases such as
dilated cardiomyopathy [1], chronic fatigue syndrome [2] and type
1 diabetes2 (T1D) [3–5].
Laboratory diagnosis of EV  infection is based on virus detec-
tion in stools, nasal/throat swabs or cerebrospinal ﬂuid, as  well
as on EV-speciﬁc antibody responses in  serum. However, studies
evaluating the pathogenesis of EV infections and their possible
role in chronic diseases (where levels of  viral infection may  be
low but persistent) require additional technologies and there is
an increasing need for direct virus detection in  tissue samples.
Traditionally, EVs are detected in tissue samples either by  RT-
PCR or immunohistochemistry3 (IHC).  In addition to these, the
new single molecule hybridization [6,7] as well  as mass spec-
trometry/proteomics technologies offer new opportunities for  viral
detection. However, there are no previous reports in which the
performance of these various technologies has been  evaluated in
relation to one another.
2. Objectives
The aim of the study was to evaluate the relative sensitivities of
proteomics, ISH, IHC and RT-PCR methods to detect one common
EV,  Coxsackievirus B14 (CVB1), using human A549 cells diluted to
contain differing ratios of uninfected to  in  vitro EV-infected cells.
3.  Study design
3.1. Preparation of EV-infected cell arrays
Human A549 alveolar basal epithelial cells were  grown in mono-
layers in Nutrient Mixture F-12Ham, N  6658 (Sigma–Aldrich®)
medium in T175 bottles and infected with CVB1, ATCC strain (10–15
MOI). The infection was stopped at four  different time points (1 h,
2  h, 4 h, and 6 h post infection) to obtain a series of infected cells
representing different stages of viral replication cycle. The cells
from different time points were mechanically detached, pooled and
washed with the growth medium. The cells were then immediately
diluted with uninfected A549 cells to produce a dilution series rang-
ing from 10−1 to 10−8, as well as an undiluted sample (positive
control) and a sample of uninfected A549  cells (negative control).
Each dilution aliquot was further divided into ten sub-aliquots, each
containing about 1 million cells. These sub-aliquots were ﬁxed or
stored in an optimal way for  each of the different methodologies
employed. Some of the aliquots were ﬁxed  in  10%  neutral-buffered
formalin for 24 h and parafﬁn-embedded using  standard proce-
dures for IHC and ISH analyses. The rest were quickly frozen in
liquid nitrogen and stored at  −70 ◦C for  RT-PCR and proteomics
analyses. From the individual formalin-ﬁxed parafﬁn-embedded5
(FFPE) samples, a cell microarray was created using TMA Master
(3D Histech Kft, Hungary) and 5 m-thick sections were cut for
histological stainings.
1 EV, enterovirus.
2 T1D, type 1 diabetes.
3 IHC, immunohistochemistry.
4 CVB, Coxsackievirus B.
5 FFPE, formalin-ﬁxed parafﬁn-embedded.
3.2. RT-PCR
RT-PCR was performed in two different laboratories (Tampere
and Uppsala), each analyzing similar aliquots of the dilution series.
In  Tampere, RNA was  extracted from 140 l  cell sample using the
Viral RNA Kit (Qiagen, Hilden, Germany), and real-time RT-PCR was
performed as previously described [8]. In  Uppsala, viral RNA was
extracted from 100 l  using RNeasy Mini  kit (Qiagen). 50  ng total
RNA/sample were primed with virus speciﬁc primers and reverse
transcribed to cDNA with SuperScriptIITM RT (Invitrogen) accord-
ing to the manufacturer’s instructions. A semi-nested EV PCR was
performed as described previously [3].
3.3. Proteomics
The dilution series samples were solubilized using 50% Tri-
ﬂuoroethanol in 50  mM ammonium bicarbonate as previously
described [9]. Protein concentration was  determined by bicin-
choninic acid6 (BCA) assay (Pierce, Rockford, Ill.). Concentration
normalized samples from each of the dilution steps were reduced
and alkylated as previously described [10]. Proteins were digested
with trypsin at a ratio of 1:50 at 37 ◦C  for  18 h to generate pep-
tides. The peptides were  puriﬁed using C18  columns, eluted using
80% acetonitrile in 0.1% formic acid and dried in  a SpeedVac.
Peptides were reconstituted in  0.1% formic acid prior to liquid
chromatography multiple reaction monitoring mass spectrometry7
(LC/MRM/MS/MS). LC/MRM/MS/MS on a  triple quadrupole (QqQ)
mass spectrometer8 provides superior rapid, sensitive, and speciﬁc
identiﬁcation and quantitation of targeted compounds in  highly
complex samples [11,12].
LC/MRM/MS analysis of the tryptic peptides from the ten A549
dilution series cell samples was performed on a 4000 QTRAP®
mass spectrometer coupled to  a Tempo NanoLC system (ABSciex,
Foster City, CA) [10]. Skyline was  used to  generate and optimize
tryptic peptides and tandem MS/MS  fragmentation data for devel-
oping MRM  transitions pairs for CVB1 peptides [13].  A CVB1 2C
protein peptide SVATNLIGR was  selected for subsequent analysis
and quantitation based  on its  abundance and high signal inten-
sities for both the precursor ion  (Q1 m/z) and fragment ions (Q3
m/z) and absence of  signals in non-infected A549 cells. MRM
Pilot TM software (ABSciex) was  used to optimize the  assay con-
ditions for  the SVATNLIGR peptide with the following transition
pairs of  465.7720/572.3515 and 465.7720/744.4363. The Q1  m/z
(465.7720) for the MH2+ peptide parent mass and the Q3 m/zs cor-
respond to y5 (572.3515) and y7  (744.4363) fragment ions. The ﬁnal
MRM  assay conditions are detailed in Supplementary data.
The tryptic peptides corresponding to 1.6 g  of  sample were
injected and  analyzed for each sample. The  samples were sequen-
tially analyzed starting with the non-infected samples and the  low
dilutions, to the non-diluted samples with  multiple washing steps
using blanks (buffer A) between each sample to avoid carry-over.
Each sample was analyzed in  duplicate experiments. Relative quan-
titation was  achieved by comparing the area under the curve for
the peptide transition pairs in  the extracted ion chromatograms9
(XIC) for each dilution step. The acquired data were processed and
analyzed using Analyst 1.2 (ABSciex).
6 BCA, bicinchoninic acid.
7 LC/MRM/MS/MS, liquid chromatography multiple reaction monitoring mass
spectrometry.
8 QqQ, triple quadrupole mass spectrometer.
9 XIC, extracted ion chromatogram.
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3.4. Immunohistochemistry
IHC was performed in  three laboratories (Tampere, Exeter and
Uppsala). Primary analyses were done using a commercially avail-
able antibody raised against EV VP110 protein (clone 5D8/1; DAKO,
Glostrup, Denmark). In Tampere and Exeter, IHC was performed as
previously described [5,14,15]. In Uppsala, the sections were coun-
terstained with haematoxylin (DAKO) before the addition of  the
primary antibody (diluted 1:2000) in  Autostainer Link 48 (DAKO).
Visualization was achieved with the DAKO Envision K8000. In
addition, polyclonal antibodies produced in rabbits (see Supple-
mentary) against each of the viral capsid proteins VP1, VP2, VP3
and VP4 of CVB4 Tuscany strain, were analyzed in  the Tampere
and Exeter laboratories. Antibodies from the ﬁrst  bleed (VP1A and
VP3A) and from the last bleed (VP1B, VP2B, VP3B and VP4B) were
used. In Tampere, staining was performed using the automated
system and similar conditions to those for clone 5D8/1. In Exeter,
following heat-induced epitope retrieval in 10  mM citrate, pH 6.0,
the VP1-VP4 antibodies were  incubated for 1 h at room tempera-
ture. The DAKO Envision Detection System was used for  antigen
detection as per the manufacturer’s instructions and sections were
counterstained with haematoxylin. The concentrations of CVB4
VP1-VP4 antibodies used in  both laboratories are detailed in Sup-
plementary Table 1.
3.5. In situ hybridization
ISH assays were performed in two laboratories (Tampere and
Gainesville). In Tampere, the QuantiGene® ViewRNA (Affymetrix,
Santa Clara, California, USA) was used with two different
EV-speciﬁc probe sets (EV AB and CVB1), according to the manufac-
turer’s instructions and as  previously described [6].  In Gainesville,
ISH was performed using the RNAscope 2.0 High  Deﬁnition Assay
(Advanced Cell Diagnostics, Hayward, California, USA) according
to  the manufacturer’s instructions. Two EV-speciﬁc probes were
tested to detect serotypes CVB1-6 and CVB3. Deparafﬁnized sec-
tions were hybridized to probes followed by ampliﬁcation by serial
application of ampliﬁers followed by  peroxidase labels and detec-
tion with DAB.
4. Results
4.1. RT-PCR
Viral RNA was detected by RT-PCR in all samples although the
semi-nested method was most sensitive. This yielded a  positive
signal from even the most dilute sample (10−8) whereas the real-
time RT-PCR method gave a  positive signal in the second most dilute
sample (10−7). Ct values from  real-time RT-PCR experiments with
different dilutions of infected cells are shown in Supplementary
Table 2.
4.2. Proteomics
MS-based targeted LC/MRM/MS/MS assay focused on the
CVB1 2C protein peptide SVATNLIGR and the  peptide signal was
detectable at cell dilutions as high as 10−7. Fig. 1shows the
LC/MRM/MS/MS results for  the relative abundance of the 2C  protein
peptide in undiluted, virus-infected cells. It also shows the  detec-
tion of the MRM  transition pairs signals, and the  enhanced product
ion scan11 (EPI) showing the MS/MS  fragmentation spectrum for
the peptide.
10 VP, viral protein.
11 EPI, enhanced product ion scan.
Table 1
Comparison of the sensitivity of different methodologies to detect CVB1 in A549
cells.
Method Sensitivity (dilution)
RT-PCR (frozen cells)
Semi-nested (Uppsala) 10−8
Real-time (Tampere) 10−7
Proteomics (frozen cells)
LC/MRM/MS/MS 10−7
MRM  10−7
IHC (FFPE cells)
Anti-EV VP1: Clone 5D8/1 10−4–10−6
Anti-CVB4 VP1, −VP2, −VP3, −VP4 10−2–10−4
ISH (FFPE cells)
Probes: EV ABa,  CVB1b (Affymetrix) 10−4
Probe: CVB1-6, CVB3 (RNAscope) 10−4
a Targets members of EV species A  and B.
b Serotype-targeted probe.
Fig. 2  shows extracted ion  chromatograms of the two transition
pairs 465.7720/572.3515 (red) and 465.7720/744.4363 (blue) for
the non-diluted, infected A549 cells (Panel A), the dilution series
of  the infected cells  (Panels B–J) and the non-infected A549 cells
(Panel K). The relative intensity and the accompanying signal for
the MRM  assay decreases from  that of the peptide.
4.3. Immunohistochemistry
IHC  also proved to be a sensitive method for detection of  viral
protein but was less  sensitive than semi-nested RT-PCR, real-time
RT-PCR and LC/MRM/MS/MS. IHC detected viral protein in virtually
every cell  in  the undiluted sample, but the proportion of  virus-
positive cells decreased linearly as the  dilution increased. Clone
5D8/1 was the most sensitive antibody tested detecting virus-
positive cells at dilutions equal to or lower than 10−4 in Uppsala,
10−5 in  Tampere and 10−6 in  Exeter. At  dilutions from 10−3 and
beyond, the number of virus-positive cells was scarce, with only
occasional cells stained positively (Fig.  3). In Tampere and Exeter,
antibodies raised against CVB4 viral capsid proteins, stained efﬁ-
ciently the infected cells diluted over the range 10−2 to  10−4.
The intensity of the staining with these antibodies varied to some
extent, with the VP1  (10−3)  and VP3 (10−4) antibodies giving the
highest sensitivities which were  comparable in both Tampere and
Exeter laboratories.
4.4. In situ hybridization
Both ISH methods (ViewRNA and RNAscope) demonstrated
equal sensitivity, regardless of the probe used, detecting the virus
at dilutions of 10−4 (Fig. 4). In the undiluted sample, almost all
cells were EV-positive, and the number of  positive cells decreased
linearly as the ratio of CVB1-infected cells  to uninfected cells was
reduced.
Comparison of  the sensitivity results between the methodolo-
gies is summarized in  Table 1.
5. Discussion
The  present study provides important information to guide the
selection of  assays capable of  optimally detect EVs  in infected cells.
Although the conditions prevailing in  mammalian cells infected
in  vitro do  not completely resemble those in clinical tissue samples,
the results provide a ﬁrm indication of  the  sensitivity and speciﬁcity
of each method.
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Fig. 1. Multiple reaction monitoring assay for CVB1 virus peptides. The total  ion chromatogram and MRM peaks are shown in panels A  and B. The  extracted ion chromatogram
(XIC)  for the Protein 2C peptide is  shown in panel C and the enhanced product ion scan (EPI)  spectrum with the Q3  y5 and y7 fragment ions are shown in panel D. These two  ions
are  the most intense in the tandem mass  spectrum and their primary sequences correspond to the following c-terminus fragments of the peptide. y5 NLIGR (m/z = 572.3515)
and  y7 ATNLIGR (m/z = 744.4363).
All methods tested were able to detect CVB1 with  good sensitiv-
ity. However, depending on the method used, the detection limit
varied and RT-PCR was found to be the  most sensitive one.
The new LC/MRM/MS/MS technology also demonstrated high
sensitivity, while its sensitivity might be  still further improved by
use of higher capacity columns that allow the loading of larger
amounts of peptides. This technology has the particular advan-
tage that identiﬁcation and validation experiments are performed
at  the same time; the overlapping extracted ion chromatograms
for the MRM  transition pairs provide conﬁrmation that the signals
are derived from the same peptide and the MS/MS  spectrum data
can be used for protein identiﬁcation in  database searches. These
data highlight the potential utility of using  modern sensitive MS
approaches to identify viral sequences with a relatively high sensi-
tivity, suggesting that its applicability for  virus detection in human
samples should be evaluated in  detail. The differences in sensitiv-
ities observed among the laboratories using IHC approaches with
the same antibody, and also the  laboratories employing ISH, could
be  explained by the low number of virus-positive cells present in
the more diluted samples. Once  these dilutions are reached, the
actual number of virus-positive cells is  very low (1–2  cells per ﬁeld);
thus, positivity may  vary from  one section to another when cells
are plated for analysis. Importantly, the different antisera tested
exhibited broadly similar proﬁles among the different laboratories
with the 5D8/1 clone consistently demonstrating the highest sen-
sitivity. ISH  sensitivity depends on a number of variables including
the afﬁnity with which the relevant probe sets bind  to the CVB1
genome. Therefore, we  cannot conclude that IHC and ISH data have
yielded absolute sensitivities in each laboratory, but  rather they
provide an  indication of the sensitivity range of each method.
Each of  the tested methods clearly has  its own  advantages.
The proteomics-based LC/MRM/MS/MS provides important molec-
ular information about the detected viruses based on peptide
sequences. We have also previously used mass spectrometry
imaging12 (MSI) to identify insulin and other proteins in pancreas
tissue since  the technology is useful for  the identiﬁcation and deter-
mination of  the spatial distribution of molecules in tissues [16].  The
preservation of tissue morphology is a clear advantage of IHC and
ISH, thereby making it  possible to localize the virus in individual
cells. ISH appeared to  be less sensitive than  IHC, but this varied
according to the type of antibodies used in  IHC. The main advan-
tage of RT-PCR is its high sensitivity and the possibility to derive
sequence information from the viral genome.
This study also has  certain limitations. Firstly, it  was  based on
infected cells  and not  ex-vivo tissue samples, and therefore the
relative sensitivity of  each assay might be  different when tissues
are examined. Secondly, a single EV strain was  used and, theoret-
12 MSI, mass  spectrometry imaging.
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Fig. 2. MRM  detection of CVB1 peptide  in A549  cells LC/MRM/MS. Extracted ion chromatograms of the two transition pairs 465.7720/572.3515 (red) and 465.7720/744.4363
(purple)  for the non-diluted CVB1 infected A549 cells panel (A), the dilution series of  the infected cells (Panels B–I) and the non-infected A549 cells (Panel J). The MRM peaks
in  the samples are marked with a red arrow. Note the absence of signal (?) in Panel J. In  panel A,  the Zoom shows an expansion of the baseline to show the well resolved
peaks  of the extracted ion chromatograms of the two MRM  transition pairs.  (For interpretation of the references to color in  this ﬁgure legend, the reader is  referred to the
web  version of this article.)
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Fig. 3. Detection of CVB1 in infected A549 and uninfected A549  cells (FFPE) with different antibodies; commercial DAKO clone  5D8/1 and in-house anti-CVB4 antibodies
VP1A,  VP1B, VP2B, VP3A, VP3B and  VP4B. Example micrographs of uninfected control, CVB1 infected undiluted sample and CVB1 infected dilution 10−1 are shown. 40×
magniﬁcation.  Scale bar = 50 m.
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Fig. 4. Detection of CVB1 in infected A549 and in uninfected A549 cells (FFPE) using two different commercially available ISH  (ViewRNA and RNAscope) methods. Example
micrographs  of uninfected control, CVB1 infected undiluted sample and CVB1 infected dilution 10−1 are shown. 40× magniﬁcation. Scale bar = 50 m.
ically, the binding of antibodies, probes and primers to different
EV  strains may  differ. However, the used antibodies bind to  several
different EV serotypes and  strains, the used PCR primers amplify
practically all EVs, the used ISH techniques allow speciﬁc probes
to be designed, enabling the detection of the virus of interest [6],
and proteomics analyses are not dependent on  the EV  type, sug-
gesting that other EV strains should give comparable results. Third,
it is difﬁcult to exclude the possibility that in spite of the repeated
washes of the infected cells  during the preparation of infected cell
arrays, remnants of extracellular viral peptides and RNA may  have
remained in the samples. This could  have led to  overestimation of
the  PCR and proteomics sensitivity, which can  detect both intra-
cellular and extracellular viruses compared to  IHC and ISH, which
mainly detect intracellular viruses. In  addition, one needs to con-
sider the fact that the sensitivity of  RT-PCR and proteomics may
depend on the sample volume, while ISH and IHC methods detect
the virus on a thin (5 m)  tissue section. Thus, the  results should be
put into the context of these limitations and the  use of more than
one of these assays is recommended to reach optimal sensitivity
and speciﬁcity.
In conclusion, all methods proved suitable for  the detection of
EV  in FFPE or frozen samples. The new proteomics technologies
offer one of the most attractive alternatives for frozen tissues, being
relatively sensitive and providing sequence information about the
detected virus. On the other hand, the new non-radioactive ISH
methods work well in FFPE samples. Even if IHC and proteomics
were relatively sensitive, RT-PCR remains one of  the most sensitive
methods when frozen or fresh samples are available. Importantly,
this effort was launched as  part of the  collaborative efforts of the
JDRF nPOD-V Working Group, and these results are guiding virus
analyses of pancreas specimens collected from T1D patients.
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